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c Concentration mg/ml 
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Fb Buoyancy force measured in contact angle 
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Δu Propagated error Eq. 20 
V Volume l 
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wt. % Weight percent % 
xc* Fraction of nuclei with critical size Eq. 7  
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Greek Letters 
α Cocrystal yield (Eq. 23) 
αf Shape factor (dimensionless) (Eq. 2) 
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δ Deformation vibration (Raman, FTIR) (m-1) 
η Kinematic viscosity (cSt) 
θ Diffraction angle in PXRD measurements (°) 
θC Contact angle of water on powders (°) 
Δμ 
Difference in chemical potential between bulk phase and newly 
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(Eq. 3) 
ν Stretching vibration (Raman, FTIR) (m-1) 
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νmol Molecular vibration frequency (s-1) 
ρ CO2 density (kg m-3) 
σ Surface tension of test liquid in contact angle measurements (Jm-2) 
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ZUSAMMENFASSUNG 
Eine wachsende Anzahl neu entwickelter Arzneistoffe ist durch hohe Lipophilie 
charakterisiert und dadurch bedingt nur schwer und langsam in wässrige Lösung zu 
überführen. Das schlechte Auflösungsverhalten dieser Arzneistoffe führt oft zu 
geringer Bioverfügbarkeit, was die therapeutische Wirksamkeit dieser Stoffe so stark 
beeinträchtigen kann, dass die Entwicklung von pharmazeutischen 
Darreichungsformen nicht praktikabel ist. Aus pharmazeutisch-technologischer Sicht 
können Löslichkeit und Lösungsgeschwindigkeit durch gezieltes Partikel-Design und 
"crystal engineering" erheblich verbessert werden.  
 Viele der etablierten pharmazeutisch-technologischen Techniken wie Mahlen, 
Umkristallisieren aus Lösemitteln oder Sprühtrocknen greifen dafür jedoch auf hohe 
Temperaturen, mechanische Belastung und organische Lösemittel zurück, was 
Kristalldefekte, chemische Zersetzung und/oder organische Lösungsmittel-
Verunreinigungen verursachen kann. Im Gegensatz dazu bietet Rapid Expansion of 
Supercritical Solutions (RESS) ein alternatives Verfahren, bei dem weder organische 
Lösemittel noch aggressive Prozessbedingungen zur Anwendung kommen. Trotz 
dieser Vorteile befindet sich das Verfahren noch im Frühstadium der 
wissenschaftlichen und prozesstechnischen Entwicklung. Das Ziel dieser Arbeit ist es 
daher, RESS als alternatives Verfahren für crystal engineering und Partikel-Design 
schwer löslicher Arzneistoffe zu untersuchen.  
 In Kapitel 2 wurde ein Prozess zur RESS Mikronisierung unter Verwendung 
von organischem Cosolvens entwickelt, da viele Stoffe mit höherem Molekulargewicht 
und polaren Funktionen eine zu geringe Löslichkeit in überkritischem 
Kohlenstoffdioxid aufweisen und daher nicht für das RESS Verfahren geeignet sind. 
Durch die Zugabe von 4 wt. % Methanol zur überkritischen Phase konnte die 
Löslichkeit des Modell-Arzneistoffs Theophyllin um einen Faktor von beinahe 25 
gesteigert werden bei gleichzeitiger Ausbeutesteigerung von rund 0 auf 25 %.  
 XII 
Durch die RESS Mikronisierung wurde dabei eine 14fache Steigerung der spezifischen 
Oberfläche erzielt. Mit steigender Expansionstemperatur konnte die Abscheidung von 
flüssigem Methanol unterdrückt werden, so dass Umkristallisierung und 
Partikelwachstum des Produkts minimiert wurden. Durch diese Weiterentwicklung 
des klassischen RESS Prozesses kann nun eine weitaus größere Anzahl an Stoffen mit 
dem RESS Verfahren mikronisiert werden. 
 In Kapitel 3 wurde die Produktion von Nanopartikeln und Nanosuspensionen 
mit Olanzapin, einem schwer löslichen BCS Klasse II Stoff, beschrieben. Mittels RESS 
konnten Nanopartikel und Nanosuspensionen mit einer mittleren Partikelgröße von 
160-340 nm und einer engen Partikelgrößenverteilung produziert werden. Besonders 
die Expansionstemperatur und der CO2 Fluss durch die Düse während der Expansion 
stellten kritische Prozessparameter dar, da bei mangelnder Kontrolle das 
Stabilisatormedium zum Einfrieren neigte oder mit dem expandierenden Gas aus dem 
Auffangbehälter ausgetragen wurde.  
 Je nach verwendetem Stabilisatormedium konnte eine Prozess-Ausbeute von 
fast 100 % erzielt werden. Aus prozesstechnischer Sicht eigneten sich sterische 
Stabilisatoren besser als elektrostatische, da sie weniger zur Schaumbildung neigten 
und die Viskosität des Stabilisatormediums erhöhten. Olanzapin zeigte allerdings 
bereits wenige Stunden nach der Herstellung der Nanosuspensionen ein mit 
Hydratbildung einhergehendes Partikelwachstum in diesen Medien. Dies konnte 
durch Zugabe von Natriumlaurylsulfat im Anschluss an den Produktionsprozess 
verhindert werden. Letztlich zeigten die Nanosuspensionen eine deutliche Steigerung 
der Auflösegeschwindigkeit von Olanzapin im Vergleich zur Referenz. Im Hinblick 
auf den Verzicht von Lösemitteln, die milden Prozessbedingungen und das erreichte 
Partikelgrößenspektrum kann das RESS Verfahren insgesamt eine bessere Alternative 
zu konventionellen Verfahren zur Herstellung von Nanopartikeln und 
Nanosuspensionen bieten.  
ZUSAMMENFASSUNG XIII 
In Kapitel 4 wurde RESS zur Produktion und gleichzeitigen Mikronisierung von 
Cokristallen aus Ibuprofen und Nicotinamid eingesetzt. Die beiden Stoffe wurden in 
unterschiedlichen molaren Verhältnissen aus der überkritischen Lösung ausgefällt. Bei 
einem Überschuss an Nicotinamid wurde der komplette Arzneistoff zum Cokristall 
umgesetzt, während bei einem molaren Verhältnis von 1:1 ein reines cokristallines 
Produkt erhalten wurde. RESS Cokristalle verfügten über eine deutlich erhöhte 
spezifische Oberfläche und eine erhöhte Auflösegeschwindigkeit im Vergleich zu 
Cokristallen, die durch konventionelle Evaporation von organischem Lösemittel 
hergestellt wurden. Im Hinblick auf die hohe Produkt-Reinheit und die 
Zusammenfassung von Produktion und Mikronisierung in einem einzelnen Schritt ist 
das RESS Verfahren eine vielversprechende Alternative zu herkömmlichen Techniken 
des crystal engineerings. 
 Abschließend kann aus pharmazeutischem Blickwinkel gesagt werden, dass 
das RESS Verfahren eine vielseitige technologische Plattform mit bisher 
unausgeschöpftem Potenzial für crystal engineering und Partikel-Design 
niedermolekularer Arzneistoffe bietet. Als umweltfreundliches Verfahren kann RESS 
den Sektor der bereits verfügbaren Technologien sinnvoll ergänzen, da einerseits 
Produkte mit vergleichbarer oder sogar überlegener pharmazeutischer Qualität 
erhalten werden können, während andererseits keine organischen Lösemittelabfälle 
anfallen oder Lösungsmittelrückstände die Toxizität der finalen Arzneiform erhöhen. 
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Introduction 
Aqueous solubility and fast dissolution are key parameters to achieve adequate 
bioavailability of active pharmaceutical ingredients (API's). But many new drug 
candidates present poor pharmacokinetic properties due to their low solubility and 
poor dissolution performance. Statistically, 40 % of new molecules are thus excluded 
from further development at the early stages of pharmaceutical research (1). This is a 
problem not only from an economical standpoint, as increasing costs of 
pharmaceutical development and limited output of successful drug candidates from 
the pipeline are the consequences. Today, a majority of the recently developed drugs 
on the market is classified as poorly soluble according to BCS (2) (Figure 1). In 
contrast, most entities listed on the World Health Organization's list of essential 
medicines from 10 years ago were still classified as well soluble, which clearly shows 
that there is an evolving trend towards more hydrophobic compounds (Figure 1). 
 
 
Figure 1 Distribution over the BCS classes of API's on the World Health Organization's 
essential list of medicines (WHO LEM) from 2003 and of new chemical entities approved by 
the Food and Drug Administration (FDA appr. NCE's) from 2011-2013 (3, 4) 
WHO LEM 2003 FDA appr. NCE's 2011-2013
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This means that there is a growing demand for strategies and processing technologies 
to increase the bioavailability of intrinsically poorly soluble compounds. From a 
pharmaceutical technological standpoint, crystal engineering and particle design are 
valuable tools to improve dissolution-limited bioavailability. There are a number of 
established processing technologies such as milling, spray drying or recrystallization 
from organic solvents, but most of them suffer from drawbacks arising from the use of 
harsh process conditions such as high temperature, mechanical stress or organic 
solvents.  
 Given the evident trend in recent drug development towards poorly soluble 
drugs and the stability issues related with conventional procedures, it is particularly 
important to develop alternative technologies. As such, the Rapid Expansion of 
Supercritical Solutions (RESS) shows great potential, because it can circumvent many 
of the problems associated with traditional techniques. RESS involves the use of little 
or no organic solvents and thus provides contaminant-free products. In addition, low-
molecular weight drugs with poor aqueous solubility often show good solubility in 
scCO2, which makes BCS Class II and IV compounds an interesting target group for 
processing with RESS. The versatility of the process has attracted growing scientific 
attention in the last years, which is mirrored by a high number of reviews, research 
papers and patents available in the literature, but much of the research is still on an 
experimental level (5, 21-25).  
 Up to date, there is no pharmaceutical product on the market that exploits 
RESS as a tool for particle design. Clearly, further scientific attention is required before 
RESS can become common practice in pharmaceutical production and development. 
For a more profound insight into the RESS process, the following sections describe its 
history, the theory of particle formation and its current status viewed from a 
pharmaceutical perspective. 
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Supercritical fluids as solvents 
In 1879, Hannay and Hogarth first observed that solids with low vapor pressure could 
be dissolved in supercritical fluids (5). They further observed that by rapidly reducing 
the pressure in a system containing a fluid and a solute, a crystalline deposit and "a 
cloud of fine crystals floating in the menstruum" were formed (5). The supercritical 
state is reached, when a gas is compressed and heated beyond its critical point, where 
the phase boundary between the liquid and the gaseous state ceases to exist. The 
critical point is located on the vapor pressure curve and is a unique property of the 
respective gas (Figure 2). The fluid state is characterized by properties similar to gases 
and liquids, but it also has unique physical characteristics. The viscosity is as low as in 
gases, facilitating both pumping and natural convection (6). The density, especially in 
the near critical region, is a function of the applied pressure and reaches liquid-like 
values at higher pressures. Because the solvent capacity of the SCF varies exponentially 
with its density, small changes in the operating conditions can specifically tailor the 
solubility of the solute or trigger precipitation. Finally, surface tension is literally non-
existent in supercritical fluids, while the diffusivity is, with 1 or 2 orders of magnitude, 
substantially higher than in a liquid (7). 
 These properties account for the solvent power of SCF's and for their 
application in mass-transfer and phase-transition processes. Figure 2 shows that by 
choosing a pathway through the supercritical region, the gaseous state can be reached 
from the liquid state without phase separation. The fluid of choice in SCF processing is 
scCO2, since its critical point is at 7.38 MPa and 31.1 °C, which provides relatively mild 
process conditions. It is also inert, non-flammable, non-toxic and environmentally 
friendly (8). CO2 is a nonpolar, hydrophobic molecule (O=C=O) with a polarity 
comparable to that of n-hexane (9). Its solvent power is thus negligible for polar 
substances and macromolecules. But for low molecular weight drugs with low aqueous 
solubility and polarizability, the solubility profile of scCO2 is often convenient. 
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Figure 2 p-T phase diagram showing 
the critical point (CP) and the 
transition from the liquid to the 
gaseous state through the supercritical 
region. Modified after (7) 
  
Supercritical fluids in particle and solid state design  
Despite the fact that SCF's have been discovered over a century ago, commercial 
applications were only established in the 1970's for the decaffeination of coffee beans 
and tea leafs (10). Most of the other industrial applications of SCF technology are in 
the field of extraction, such as hops and essential oils, and analytical chromatography 
(10). Apart from extraction and chromatography, SCF technology comprises several 
applications for particle formation and design. These techniques are particularly 
interesting from a pharmaceutical perspective, but are so far only used on laboratory 
scale. One reason for this is that the cost of instrumentation and operation in high-
pressure systems is comparably high (10).  
 SCF technology for particle design can be broadly classified into 2 groups, 
namely solvent and antisolvent techniques (Table 1). In solvent techniques, the 
processed compound is dissolved in a SCF; sufficient solubility is thus a prerequisite. 
In antisolvent techniques, an API is dissolved in an organic solvent and emulsified 
with an aqueous phase containing optional excipients. The organic solvent is then 
extracted with scCO2, so that micelles of the API in the watery phase remain.  
 6 
On the one hand, antisolvent techniques allow processing of a wider range of materials 
because solubility in the fluid is not a prerequisite. But on the other hand, un-extracted 
residual solvents can lead to re-agglomeration of the products and increase their toxic 
potential, thus contradicting one of the most important initial advantages of SCF 
technology (10). Controlled Particle Deposition (CPD) and the Rapid Expansion of 
Supercritical Solutions (RESS) are solvent-based techniques that use SCF’s (Table 1). 
In CPD, the pressure is released from the dissolution chamber, so that the dissolved 
material is precipitated directly into porous carriers that are placed in the chamber 
together with the API. It has been used for the formation of drug-loaded carriers and 
an inclusion complex of ibuprofen in cyclodextrins (11, 12). Disadvantages of this 
technique are solute loss via the vent, when the reaction chamber is depressurized, and 
unspecific particle deposition inside the reaction chamber. In addition, it is difficult to 
ensure homogeneous conditions throughout the dissolution chamber and throughout 
the duration of the expansion, so that broad particle size distributions may result.  
 In contrast to this, the expansion of the supercritical solution in the RESS 
process is controlled through a capillary nozzle. The spray expansion lasts for less than 
10-5s, so that the pressure and density of the fluid drop very rapidly. At the same time, 
the solvent power of the SCF, which is a direct function of the fluid density, is reduced 
drastically. As a result, the solute is precipitated on a submicron or micron scale (13, 
14).  
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Table 1 Supercritical Fluid based techniques for particle formation 
Solvent based techniques Antisolvent based techniques 
 
• Rapid Expansion of Supercritical 
Solutions (RESS) (13, 14) 
• Controlled Particle Deposition 
(CPD) (11, 12) 
 
• Particles from Gas-Saturated 
Solutions (PGSS) (15) 
• Gas Antisolvent Process (GAS) (16) 
• Supercritical Antisolvent Process 
(SAS) (17, 18) 
• Precipitation from Compressed 
Antisolvent (PCA) (19), 
• Solution Enhanced Dispersion by 
Supercritical Fluids (SEDS) (20) 
• Supercritical Antisolvent Process 
with Enhanced Mass Transfer (SAS-
EM) (21) 
 
 
Particle formation with RESS 
The supersaturation S is the driving force for all solution crystallization processes. The 
supersaturation is the difference between the actual concentration and the equilibrium 
concentration of a solute at given conditions and is a determining factor for the 
resulting particle size distribution. S is defined as: 𝑆 = !!        (!!;!!)!∗   !;!   Eq. 1 
Where yE is the solute mole fraction at the extraction temperature and pressure (TE; pE) 
and y* is the equilibrium mole fraction of the solute at the actual temperature and 
pressure of expansion (p;T) (22). Nucleation means the birth of new crystal nuclei via 
random aggregation of molecules.  
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It is followed and partially superposed by particle growth that is driven by 
condensation, when single molecules are added at the particle surface, and 
coagulation, when collisions of separate particles form bigger ones (23). The 
supersaturation controls these competing mechanisms and influences the resulting 
crystal size. At low supersaturation, crystals can grow faster than they actually 
nucleate, so that fewer and larger crystals are formed (Figure 3). With increasing 
supersaturation, the nucleation rate increases exponentially, which is why in these 
cases; a high number of small crystals are formed. This is the underlying principle of 
RESS micronization.  
 The theory of nucleation in RESS can be explained analogous to classical 
nucleation theory (CNT) and the kinetic models assumed for nucleation and particle 
growth developed by Volmer and Weber (24) and Becker and Döring (25). In CNT, 
the free energy of nucleus formation Fn for a nucleus comprising n molecules is 
described as: 𝐹! = 𝛾𝛼𝑛!! − 𝑛∆𝜇  Eq. 2 
Where γ is the interfacial tension between the medium and the newly created bulk 
phase, α is a shape factor to account for nuclei that are not spherical in shape, and Δµ 
is the difference in chemical potential between the phases. 
 
Figure 3 Influence of 
supersaturation on crystal size 
through growth and nucleation 
rate 
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Δµ is the driving force for the phase change and can be expressed as: 𝛥𝜇   =   𝑘!𝑇  𝑙𝑛𝑆  Eq. 3 
Where kB is the Boltzmann constant, T is the temperature and S is the 
supersaturation1. Basically speaking, the term 𝛾𝛼𝑛!! describes the energy cost of the 
system due to the creation of a new interface, while the term 𝑛∆𝜇 describes the energy 
gain due to the formation of a new stable phase from a metastable state. To account for 
the fact that not all nuclei are spherical, a shape factor α can be introduced in Eq. 2 
while replacing r with n as the number of molecules inside the nuclei. By plugging Eq. 
3 into Eq. 2, Fn becomes: 𝐹! = 𝛾𝛼𝑛!!   −   𝑛𝑘!𝑇  𝑙𝑛𝑆  Eq. 4 
In Figure 4, the free energy of nucleus formation Fn is plotted against the nucleus size. 
As the creation of a new interface costs energy, nucleation will not proceed if the 
formed nucleus is too small, because the energy released by forming its volume is not 
enough to create its surface. This is only the case when the critical nucleus size n* is 
reached. At n*, the sum of these energies reaches a maximum Fn*, which is also called 
the nucleation barrier. At this point, the free energy Fn of the system will be reduced, 
whether the nucleus grows or dissolves. Nuclei with critical size are thus in a 
thermodynamically metastable state. 
                                                            
1 In many publications, Eq. 3 is expressed as 𝛥𝜇   =   𝑘!𝑇  ln   !!!!"# . The activity ratio !!!!"# can 
however be approximated by the ratio of concentrations, or S. 
 10 
 
Figure 4 Free energy of nucleus 
formation Fn as sum of interface free 
energy and bulk free energy in 
dependence of the nucleus size. 
Modified after (26) 
  
The critical nucleus can be calculated by setting the first derivative of Eq. 4 to zero and 
solving it for n: 𝑛∗ = !!"!!!!  !"# !  Eq. 5 
The critical energy or nucleation barrier can then be calculated as: 𝐹!∗ =    !(!")!!"(!!!  !"#)!  Eq. 6 
Nucleation is basically the result of random fluctuations that bring together sufficient 
numbers of molecules to form a nucleus that exceeds the critical size. The smaller the 
critical nucleus size becomes, the higher is the probability for this energy fluctuation to 
occur. This is exactly the case, when the supersaturation S is increased.  
The probability of energy fluctuation of the size Fn* is given by: 𝑥!∗   ≅   𝑒𝑥𝑝 !!!∗!!!   Eq. 7 
Where xc* is the fraction of nuclei with critical size, which is defined as: 𝑥!∗ ≅ !∗!!     Eq. 8 
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With c1 being the concentration of monomers in the system, assuming that it is much 
greater than the concentration of critical nuclei c*, T is the temperature and kB is the 
Boltzmann constant. Combining Eq. 7 and Eq. 8, the concentration of critical nuclei c* 
is given by 𝑐∗   ≅   𝑐1  𝑒𝑥𝑝 !!!∗!!!   Eq. 9 
For the nucleus to grow, an atom or molecule must overcome the energy barrier ΔGm 
to cross the interface separating the nucleus and the matrix.  
The frequency of atom or molecule incorporation into the nucleus νinc is described by 
another Boltzmann distribution: 𝜈!"#   =   𝜈!"#𝑒𝑥𝑝 !∆!!!!!   Eq. 10 
Where 𝜈!"#  is the vibration frequency of the molecule at a temperature T, ΔGm is the 
activation free energy for the molecule to cross the interface, kB is the Boltzmann 
constant and T is the temperature. Combining the 2 conditions given by Eq. 9 and Eq. 
10, one arrives at a simplified description for the nucleation rate J, which is defined as 
number of nuclei formed per unit volume in unit time:  𝐽   =     𝑐  𝑍    𝑒𝑥𝑝 − 𝐹!∗𝑘!𝑇   𝑒𝑥𝑝 − Δ𝐺!𝑘!𝑇  Eq. 11 
Where c is the number of atoms or molecules per unit volume and Z is the Zeldovich 
factor, which essentially expresses the probability of a nucleus with the energy Fn* 
going on to form the new solid phase instead of dissolving back (27). Using Eq. 6, Eq. 
11 can be written as: 𝐽   =     𝑍    𝑒𝑥𝑝 !!!!!     Eq. 12 
Here, all other factors except the supersaturation and the interfacial tension are 
grouped into a factor B. Eq. 12 shows how strongly J depends on the supersaturation S 
and the interfacial tension γ, as they come in the 2nd and 3rd powers in the argument 
of an exponential.  
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Modeling of the particle size in RESS 
For RESS to become a common processing technique for particle formation, control 
over both particle size and morphology is crucial for its further development up to 
commercial feasibility. For that reason, mathematic modeling has been important 
from the early stages of RESS research (22, 28, 29). Models to predict particle size 
include the nucleation process analogous to CNT and, as a significant determinant of 
the final particle size, the particle growth due to condensation and coagulation (22, 23, 
30). CNT was derived on the assumption of equilibrium conditions, which is not the 
case in RESS (13). Corrections of CNT are thus necessary due to the non-ideality of 
SCF's. For example, their liquid-like density coupled with high compressibility causes 
a decrease of the solute concentration upon expansion and a sharp drop of the 
temperature, thus increasing the critical nucleus size and decreasing the attainable 
nucleation rates (28, 29).  
 The so far developed RESS models focus on the influence of the process 
conditions and equipment on the expansion process, such as pre- and post expansion 
temperature and pressure, nozzle geometry and length. The variables included are the 
fluid density, the flow area, the velocity of the fluid, the distance along the expansion 
device, friction in the capillary, and the enthalpy, heat and pressure of the system (31). 
Given the necessary simplifications for reasonable calculations, the diversity of particle 
growth mechanisms taking place simultaneously2 and the difficulty of accounting for 
all flow phenomena inside the exact geometry of the expansion chamber, the 
predictability of particle size and morphology with the current models is to a certain 
degree inaccurate. In addition, many of the proposed calculations yield reasonable 
results when applied to the particular study in which they were derived, but often 
contradict those of other publications in the field (23).  
                                                            
2 These include particle growth due to condensation, coagulation and/or Ostwald ripening.  
CHAPTER 1 | Introduction and Aim of this Thesis  13 
According to most models, the particle size at the end of the supersonic freejet 
expansion is in the range of 10- 50 nm (23, 31). Although the calculation models 
somewhat lack precision, this raises the question why experiments yield particle sizes 
that exceed these models by 1 or 2 orders of magnitude. The reason for this is probably 
that particle growth in the supersonic expansion freejet is unfinished, but continues 
during the subsonic freejet and/or the residence time of the particles inside the 
expansion chamber (31). The major part of the growth time is spent outside the 
nozzle, which means that the influence of the pre-expansion conditions on the final 
particle size might be over-estimated, while the conditions inside the expansion 
chamber are key factors that are often not yet included in the models (23, 31). 
Restriction of particle growth inside the expansion chamber could, for example, be 
achieved by lowering the collision frequency and efficiency by choosing low pre-
expansion solute mol fractions and lower temperatures (23, 32). All in all, there are 
promising approaches to be found for modeling of the RESS process, but it is still in 
development and especially the issue of particle growth during the residence time 
needs to be investigated more thoroughly.  
Is there a place for RESS in pharmaceutical technology? 
As explained initially, most applications of RESS are still on an experimental level. To 
date, no commercial applications for particle formation and design exist in the 
pharmaceutical field. The reasons for this can be mainly seen in the following issues: 
• Predictability and control of the particle size and size distribution are often 
poor. 
RESS modeling often does not yet succeed to reliably predict the final particle sizes, 
because the determining factors that influence particle growth are not yet fully 
understood (page 12). As a result, micron-sized particles with broad size distributions 
are often obtained. 
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• The solubility of many compounds in scCO2 is too low. 
As discussed initially, the solubility profile of scCO2 is restricted to low molecular 
weight drugs and such that are rather non-polar (page 4). Even if these properties are 
met, it is still difficult to achieve solute concentrations that are comparable to organic 
solvents. The process is thus often regarded as economically unfeasible because of the 
low throughput rates. 
• The process yield of RESS is often low due to inefficient separation of the small 
particles from the gaseous stream.  
Similar to spray drying, where a solution of a drug is atomized via a nozzle and 
collected in a tower or cyclone, optimization of the particle yield in RESS is of utmost 
importance. The separation efficiency depends on the speed of the travelling particles, 
their size and of course the geometry of the expansion device. With the currently used 
equipment, presumably a large fraction of the fine material is not separated from the 
gaseous stream. This becomes evident by the low process yields often reported in the 
literature, which are mostly below 5 % (33). It is also possible that the discrepancy 
between calculated and experimental particle size is partially caused because of this 
phenomenon (see page 12). 
• Joule-Thompson cooling during the expansion process can cause process 
disruptions because of (dry) ice formation or nozzle blockage. 
As described before, the spray expansion of the supercritical solution occurs in less 
than 10-5 s (page 5). Due to the rapid expansion of a large amount of gas, the 
temperature inside the expansion chamber can drop to -50 °C within seconds. Heating 
mantles can often not compensate that, so that it is vital to control the mass flow of 
CO2 through the nozzle. The drastic temperature drop can cause formation of dry ice, 
freezing of water if present, and blockage of the nozzle so that the expansion process is 
disrupted. 
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So clearly, there is a need to dedicate further scientific attention to these issues before 
RESS can become common practice as a pharmaceutical processing technique. And 
although the research published on RESS for the improvement of solubility and 
dissolution is promising, there are fundamental questions that remain to be addressed. 
At the same time, RESS offers a number of advantages over established processing 
techniques that justify further scientific effort and make its development worthwhile. 
Figure 5 summarizes the advantages of RESS from a pharmaceutical perspective. The 
most important aspect certainly is that in contrast to traditional procedures, it involves 
the use of little or no organic solvents. This avoids large organic waste streams and 
renders the process environmentally friendly, which is particularly important in 
today's environment that is increasingly focused on sustainability (34). At the same 
time, RESS avoids organic solvent contamination in the products, which would 
increase their toxic potential, call for complex purification steps and analytical control 
of the residual levels.  
 In contrast to organic solvents, scCO2 is non-toxic, environmentally friendly, 
non-flammable, relatively cheap and inert. With its critical point located at 7.38 MPa 
and 31.1 °C, scCO2 offers very mild processing conditions. In contrast, conventional 
size reduction techniques often impart high mechanical stresses on the material, which 
can cause degradation of thermo-labile compounds due to heat generated by attrition, 
polymorphic conversions and damage of the crystallinity.  
 Compressed gases can be easily recycled after expansion without the need of 
further purification, because once returned to the gaseous state, they have negligible 
solvent power (13). From a process-engineering standpoint, this allows easy in-process 
recycling of the SCF, which helps to reduce the production cost in a pharmaceutical 
batch operation or could even help to design a continuous process (10). In addition, 
the solubility profile of scCO2 is convenient for processing of hydrophobic, low-
molecular weight drugs, which is also the target group usually processed by 
conventional micronization techniques.  
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Finally, one of the most attractive features of the RESS process is clearly its versatility, 
as a number of applications can be realized with basically the same technology. In the 
pharmaceutical literature, the largest part of the research is focused on micronization 
of poorly soluble drugs (14, 35-39). There are also a number of publications that 
describe RESS as a tool for the production of nanoparticles and nanosuspensions (40-
44). In addition, a few reports assess RESS in the field of crystal engineering, i.e. for the 
formation of different polymorphs or crystal doping (45-47). Polymer processing with 
RESS has high potential but lies beyond the scope of this work and will therefore not 
be addressed further. For these aspects, reference is made to previous publications (40-
42, 44, 48-51).  
 
 
Figure 5 Summary of process advantages of the Rapid Expansion of Supercritical Solutions 
(RESS)  
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Aim of this thesis 
A growing number of newly developed drug candidates often need to be excluded 
from pharmaceutical development due to insufficient solubility and, as a result, poor 
pharmacokinetics. At the same time, traditional pharmaceutical techniques to process 
such compounds can cause instabilities that arise from using harsh process conditions 
such as elevated temperature, mechanical stress or organic solvents. In this light, there 
is a definite need to develop alternative technologies such as the Rapid Expansion of 
Supercritical Solutions (RESS). Although the technique offers immanent advantages 
such as little or no use of organic solvents and very mild process conditions, its use in 
the field of pharmaceutical particle design and crystal engineering is still on an 
experimental level. Clearly, some fundamental issues need to be addressed before the 
technique can become common practice in pharmaceutical development and 
production. These issues concern: 
 • Control of the critical product parameters such as the particle size 
distribution 
• Solubility in supercritical carbon dioxide 
• Process yield 
• Control of the critical process parameters such as the expansion cooling  
 
The aim of this thesis is to investigate the potential of RESS as an alternative 
pharmaceutical processing technique for crystal engineering and particle design to 
improve aqueous solubility and the dissolution performance of poorly soluble drugs. 
To this end, each of the central chapters focuses on the development of a specific RESS 
application. Chapter 2 investigates whether liquid-cosolvent assisted RESS 
micronization is a feasible approach to increase drug solubility in supercritical carbon 
dioxide and thus RESS process yields. Chapter 3 assesses RESS as an alternative 
technology for the production of nanosuspensions as a potential pharmaceutical 
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dosage form. Chapter 4 investigates RESS as a tool for the simultaneous formation 
and micronization of pharmaceutical cocrystals. Each chapter includes a 
pharmaceutical characterization of the products to evaluate the quality of the 
processed material in terms of purity, particle characteristics and, in Chapter 3 and 4, 
dissolution rate. At the same time, the above-mentioned issues associated with RESS 
are addressed and discussed in the respective context. Ultimately, this thesis should 
help to disclose the potential of processing low molecular weight API's with poor 
aqueous solubility via RESS and thus support the technique's further development in a 
pharmaceutical environment. 
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CHAPTER 2 | COSOLVENT-ASSISTED RESS MICRONIZATION  
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Introduction 
A large fraction of research conducted in the field of RESS is focused on micronization 
of poorly soluble drugs to enhance solubility and dissolution (14, 31, 36, 39, 52, 53). 
But the restricted solvent capacity of SCF's does not allow a wide range of material to 
be processed with RESS (54). The described advantages of using CO2 as a fluid in the 
pharmaceutical sector are opposed by its low polarizability. CO2 is a Lewis base, 
because it can donate an electron pair to Lewis acceptors. Acid/base, induced dipole 
and quadrupole interactions provide scCO2 with a limited solvation power, which is 
however not great enough for high molecular weight and/or polar compounds (55). 
The solubility in scCO2 of these compounds is not sufficient to be economically 
acceptable.  
 From the field of SCF chromatography and extraction, it is known that the 
polarity of the SCF can be modified by addition of a cosolvent to increase the solubility 
of many compounds (56). A commonly used polar modifier in SCF chromatography 
and extraction is methanol (57). The p-T-x behavior of the binary system CO2 + 
methanol has been thoroughly examined (58-63). Methanol is highly soluble in CO2 
and completely miscible with scCO2 above 15.6 MPa in a temperature range from 0 -
 120 °C and at 0 - 20 mol % (55). Depending on the fraction of methanol added to CO2 
and the applied pressure, the dielectric constant of the mixture can be increased 
distinctly.  
 In the case of xanthines, this was found to significantly enhance their solubility 
in scCO2 (56). Theophylline (TP) is a methylxanthine drug used in the treatment of 
respiratory diseases, since it acts as a competitive nonselective phosphodiesterase 
inhibitor and raises intracellular cAMP (Figure 6). At 40 °C and 22 MPa, the solubility 
of TP in scCO2 is very low with 9.77 x 10-6 mol fraction (64). It has thus been mainly 
processed with supercritical antisolvent techniques (65-69). With the addition of 
methanol to the supercritical phase, it is however possible to increase the solubility of 
TP by an order of magnitude (56).  
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The solubility enhancement in scCO2 is a prerequisite for TP to be successfully 
micronized with RESS. It is however vital to consider what happens to the cosolvent 
when the ternary mixture of scCO2, cosolvent and API is sprayed into the expansion 
chamber. Upon depressurization, it is possible that the supercritical mixture is 
separated into a liquid methanol phase and a gaseous CO2 + methanol phase. In that 
case, the cosolvent that is precipitated in liquid state can cause dissolution and 
recrystallization of the micronized product during the residence time in the expansion 
chamber (70). The product might also be contaminated with remnant solvent and 
need further purification steps. Due to these issues, liquid cosolvents have been rarely 
applied in the RESS process and the literature on that matter is sparse (43, 51, 54, 71, 
72). Up to date, there is no systematic investigation about the effect that a phase 
separation of the organic solvent has on the product and how that could be avoided. 
 
Figure 6 Chemical structure of theophylline 
  
 
The p-T region, where such a phase separation can be expected to occur, can be 
derived from the isothermal phase equilibria of binary mixtures of methanol and CO2 
(Figure 7a). In that representation, the area inside the envelopes is two-phase, gas and 
liquid, while the outside of the envelopes consists of a single phase. The implications of 
this shall be explained with the following example: The process conditions P in Figure 
7 mark a cosolvent mass percentage of 4 wt. % and a post expansion pressure of 1.0 
MPa. If the temperature during RESS expansion is at 25 °C, the liquid-vapor line will 
be crossed resulting in a phase separation. If the temperature during the expansion was 
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to be kept at 50 °C, then these process conditions would fall outside the envelope, 
meaning that a homogeneous gaseous phase would be maintained. It is hypothesized 
that by careful control of the expansion temperature and pressure, a liquid phase 
separation of methanol during liquid cosolvent-assisted RESS can be suppressed, so 
that a micronized product with a homogeneous particle size distribution can be 
obtained. To test this hypothesis, the solubility of TP with different amounts of 
cosolvent was measured. With a suitable cosolvent addition, RESS products of 
theophylline were produced at 3 different temperature intervals and the particle 
morphology, specific surface area and size distribution for each product was analyzed. 
In addition, a solid state analysis via FTIR and PXRD was included to assess the 
influence of RESS precipitation and the presence of methanol on the polymorphism of 
the drug. 
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a) 
 
b) 
 
Figure 7 a) Binary isothermal phase equilibria of CO2 + methanol at 25, 50 and 100 °C. The 
area inside the envelopes is two-phase. Data from (58); b) exemplary process conditions P 
(1 MPa, 4 wt. % methanol) 
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Materials and Methods 
Materials 
Theophylline was obtained from Böhringer Ingelheim, Biberach, Germany. Methanol 
was purchased from Avantor, Deventor, The Netherlands, and carbon dioxide was 
purchased from Air liquide, Düsseldorf, Germany. 
Methods 
Pilot unit for high-pressure micronization 
The pilot unit that was used for high-pressure micronization is shown in Figure 8 
(Sietec-Sieber, Maur, Switzerland). Carbon dioxide (CO2) was used as solvent in all 
experiments. The machine comprises a tank, where CO2 is cooled down to liquid state 
(Figure 9). Liquid CO2 is then conveyed via a high-pressure pump into the extraction 
chamber, heated and pressurized to supercritical conditions.  
  
 
Figure 8 Pilot unit used for high 
pressure micronization 
  
The CO2 flow can be adjusted in a range of 0 to 30 kg/h and the mantle temperature of 
the extraction chamber can be heated up to 70 °C. After the equilibrium time, the 
supercritical solution is expanded into the expansion chamber through a capillary 
nozzle with a diameter of 150 µm. The flux through the nozzle needs to be controlled 
manually with a micro-metering valve. The process parameters (temperature and 
CHAPTER 2 | Cosolvent-Assisted RESS Micronization 25 
pressure of the extraction and expansion chamber, mass flow, CO2 density in the 
extraction chamber) are monitored with the software VisiDAQ Runtime version 3.11. 
To increase the particle yield and the process efficiency, several modifications of the 
original expansion path that was designed by Sietec-Sieber were tested. Further details 
can be found in the Appendix. 
 
Figure 9 Schematic of the pilot unit for high-pressure micronization 
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Micronization of theophylline with the RESS process 
1.0 g of anhydrous theophylline was placed into the extraction chamber, which was 
then flooded with CO2, heated to 50.0 °C and pressurized to 30 MPa. If cosolvent was 
used (2 or 4 wt. % in scCO2), it was placed into the extraction chamber together with 
the solid material. The cosolvent mass was calculated as 𝑚!"#$% = 𝑤!"#$% ∙   𝜌  𝐶𝑂!(𝑝!;𝑇!)    ∙   𝑉!"# Eq. 13 
Where 𝑤!"#$%  is the mass fraction of methanol, 𝜌  𝐶𝑂!(𝑝!;𝑇!) is the CO2 density at 
the respective extraction conditions (9) and 𝑉!"#  is the volume of the extraction 
chamber. The solution was left to equilibrate for 3 h or 18.5 h. After the equilibration 
time, the solution was expanded into the expansion chamber at a post expansion 
pressure of 1.0 MPa and 3 different temperature intervals (Table 2). The expansion 
chamber was equipped with a filter cartridge for particle collection as shown in Figure 
10.  
 
 
 
Figure 10 Device for particle collection 
used in the expansion chamber 
 
 
The heating mantle of the expansion chamber was set to 70.0 °C. This alone was 
however not sufficient to compensate the expansion cooling so that the actual 
temperature control was achieved via adjusting the mass flow of CO2 through the 
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micro-metering valve (Table 2). This naturally reduced the throughput of the process, 
which is why longer expansion times were chosen for RESS experiments conducted at 
the higher temperature intervals (Table 2). To monitor the temperature, 2 
thermocouples T1 and T2 were used (Figure 10). T1 was placed in close proximity to 
the fluid exit at the nozzle and T2 at the bottom of the expansion chamber. It was 
assumed that the maximum temperature drop occurred in close proximity to the 
nozzle exit, so that the positioning of T1 allowed the detection of the lowest 
temperature inside the expansion chamber. The temperature fluctuations measured 
with T1 were quite drastic, because partial or total blockage of the nozzle could cause a 
difference of more than 10 °C in a couple of seconds. Without a nozzle heating or an 
automated control, this could not be prevented effectively. But, more importantly, the 
temperature at the bottom of the expansion chamber was more stable and generally at 
least 15 °C higher than at T1. The temperature at T2 was considered crucial, because 
liquid methanol collected in the lower part of the chamber would certainly cause 
recrystallization of the product during the residence time. 
Table 2 Process conditions for the production of RESS theophylline at temperature intervals 1-
3. Mean values represent average values ± standard deviation of 3 individual RESS experiments 
Sample Temperature in the 
expansion chamber (°C) 
Mass flow CO2 
(kg/h) 
Time of 
expansion (min) 
T1 T2 
RESS TP 1 > 0 < 15 11.2 ± 0.39 120 
RESS TP 2 > 15 < 30 1.49 ± 0.12 300 
RESS TP 3 > 30 > 50 0.51 ± 0.22 300 
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Calculation of the RESS process yield 
The process yield PY of RESS experiments was calculated as wt. % in relation to the 
dissolved material mD : 𝑃𝑌   =   !!!! ∙   100  Eq. 14 
Where mE is the mass of the RESS product recovered from the expansion chamber.  
Solubility measurements in supercritical carbon dioxide and calculation of 
solubility 
The solubility s of the employed materials in scCO2 was measured with a static 
gravimetric approach (9). An accurately weighed amount of the respective material 
was placed inside the extraction chamber, which was subsequently flooded with CO2, 
heated and pressurized to the desired experimental conditions. After the equilibration 
time, the extraction chamber was depressurized and the remaining solid was removed 
and weighed again. The solubility sCO2 was calculated as g/kg of dissolved API in scCO2 
(mD) at the respective extraction conditions or as molar fraction y of the API in scCO2: 𝑠!"!   =    !!   !"#!   !!!  !!;!!   Eq. 15 
 𝑦   =    !"#  (!"#)!"#  (!!!!!;!!)  Eq. 16 
 
The mass of CO2 was calculated as 𝑚  𝐶𝑂! =   𝜌  𝐶𝑂!  !;! ∙   𝑉!"# Eq. 17 
Where 𝜌  𝐶𝑂!  !;!  is the density of scCO2 at the respective extraction conditions. The 
pressure (p) and temperature (T) were recorded over the extraction time  
(VisiDAQ Runtime software version 3.11) and the respective density data was taken 
from the literature (9). The volume of the extraction chamber 𝑉!"# was 5.033 l.  
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Particle size measurement via Laser Diffractometry in dry dispersion 
A Mastersizer 2000 (Malvern, Herrenberg, Germany) equipped with a dry dispersion 
unit (Scirocco 2000) was used. For The disperser pressure was set to 0.35 MPa. The 
particle size distribution (PSD) was characterized by the median particle size (Dv50) 
and the particle size distribution width (span) was calculated based on the 10 %, 50 % 
and 90 % quantile: 𝑆𝑝𝑎𝑛   =   !!!"  !!!!"!!!"   Eq. 18 
Particle size measurement via Dynamic Light Scattering (DLS) 
The particle size and particle size distribution (PSD) of RESS theophylline produced at 
the third temperature interval was measured using a Zetasizer Nano ZS (Malvern, 
Herrenberg, Germany). An amount of 10 mg of RESS TP particles was suspended in 
1 ml of demineralized water that was previously saturated with theophylline. All 
samples were diluted 1:4 and equilibrated during 120 s at a cell temperature of 20 °C. 
Each sample was measured 3 times and the average values of 3 individual RESS 
batches are reported.  
Measurement of the specific surface area with the Brunauer-Emmet-Teller 
(BET) method 
The specific surface area was measured with nitrogen gas adsorption at -196 °C. The 
material was accurately weighed and analyzed with a SA 3100 Beckman Coulter 
system (Beckman Coulter, Krefeld, Germany). The outgas temperature was set to 
100 °C at an outgas time of 120 min. The average results reported are those of 2 
individual RESS batches. 
Scanning Electron Microscopy (SEM) 
The surface morphology and particle shape were examined using a scanning electron 
microscope (DSM 940 A, Zeiss, Oberkochen, Germany). Pictures were taken using the 
Orion 5 frame grabber system (E.L.I. Microscopy, Charleroi, Belgium). The RESS 
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material was directly precipitated onto microscopic slides, which were then coated 
with gold with a sputter coater (E5100, BioRad, München, Germany). All samples 
were sputtered 4 times over 60 s at 2.1 kV and 20 mA.  
Differential Scanning Calorimetry (DSC) 
Measurements were performed using a DSC system (TA 8000, DSC 820, Mettler 
Toledo, Germany). The samples (4.5 – 5.5 mg per run) were placed in perforated 40 µl 
aluminium standard pans and crimped with punched lids. An empty aluminum 
sample pan was used as reference. A temperature range from 25 °C to 300 °C was 
scanned at a heating rate of 10 K to determine the melting points (onset temperature, 
Ton) and the specific heat of fusion (ΔHf). The heat of fusion was obtained by 
integration of the melting peak areas (software STARe SW 8.10). The average results 
reported are those of 3 individual RESS batches. 
Powder X-Ray Diffraction (PXRD) 
The X-ray powder diffractograms were recorded at room temperature (Philips PW 
1730 diffractometer, NL) using a Cu Kα radiation source with an automatic data 
acquisition (APD Philips v.35B). The equipment was set to a range of 2θ from 7 to 35
° in the continuous mode, with a step size of 0.015° (2θ) and an acquisition time of 
1 s/step. Samples were mounted on an aluminum sample holder and the current and 
voltage of the tube set to 30 mA and 40 kV, respectively. 
Fourier Transform Infrared Spectroscopy (FTIR) 
Measurements were performed using a Nicolet 380 FT-IR spectrometer in absorbance 
mode (Thermo scientific, Karlsruhe, Germany). A total of 30 scans was performed 
over a range of 4000-400 cm-1 at a scan speed of 0.5 cm/s. The second derivative of the 
FTIR spectra was calculated using the OMNIC software (Thermo scientific, Karlsruhe, 
Germany). 
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Results & Discussion 
Solubility of theophylline in supercritical carbon dioxide 
The solubility of theophylline (TP) was measured in dependency of the amount of 
methanol and the extraction time (Table 3). Without methanol, the solubility of TP 
was 0.011 ± 0.0002 g/kg CO2 at 30 MPa and 50 °C after 3 h of extraction time. 
Literature data of TP solubility in scCO2 without methanol as cosolvent at a 
temperature of 40 °C and 22 MPa is reported as 0.04 g/kg (56) 3. With 4 wt. % 
methanol, the solubility of TP could be increased by almost one order of magnitude 
(0.096 g/kg CO2; Table 3) after an extraction time of 3 h, which is in good agreement 
with the literature (56). By increasing the extraction time to 18 h, the solubility of TP 
could be more than doubled (Table 3). With these measures, the dissolved amount of 
TP could be increased by a factor of almost 25 in comparison to the shorter extraction 
time and the absence of cosolvent. At these conditions, it was possible to produce a 
RESS TP with sufficient yield for further characterization. 
  
                                                            
3 The discrepancy between the results here and those in the literature are probably due to the 
different methods of measurement. The static gravimetric approach that was used here is the 
method that is most susceptible to errors, because the solute is in contact with the SCF for a 
long time until equilibrium is reached. During long holding times, slight changes in pressure 
and temperature will change the dissolved mass. Gravimetric sampling is furthermore only 
recommended for solutes that exhibit solubility greater than 10-3 mol fraction, which is not the 
case for TP (the TP solubility is in the range of 10-6 mol fraction). With the equipment at hand, 
no other method of measurement could be conducted, so that the presented results here cannot 
be entirely comparable with more accurate results given in the literature. Nevertheless, a good 
agreement with literature results was obtained when looking at the proportionality of the 
solubility increase with and without methanol, although the solubility results obtained here are 
in general lower than the values found in the literature. 
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Table 3 Solubility sCO2 (g/kg CO2) in dependency of the amount of cosolvent and the extraction 
time 
Extraction time 
(h) 
Amount of cosolvent (wt. %) 
0 0.5 2 4 
3 0.011 ± 0.0002 0.015 ± 0.003 0.049 ± 0.023 0.094 ± 0.003 
18 n.a. n.a. 0.114 ± 0.005 0.267 ± 0.017 
n.a. not analyzed 
Process yield of RESS experiments with and without cosolvent 
Without methanol as cosolvent, the product yield of RESS TP was so low that a 
gravimetric determination was not possible. With an addition of 4 wt. % of methanol, 
the yield could be distinctly increased up to 25 %. At the first temperature interval 
(RESS TP 1; T2 < 0 °C), the obtained RESS product consisted of a liquid methanol 
phase, which entirely dissolved the precipitated particles. At the following intervals 
(RESS TP 2; T2 < 30 °C and RESS TP 3; T2 > 50 °C), macroscopically dry powder 
products were obtained. 
Particle size and morphology of RESS theophylline 
SEM images of unprocessed TP showed anisometric large particles (Figure 11a). In 
comparison, the particle size of RESS TP was distinctly reduced. In the case of RESS 
TP 2, the powders showed clear signs of recrystallization as a probable consequence of 
a liquid-gas phase separation during the expansion process and consequent partial 
dissolution of the precipitated material due to liquid methanol. Long adhering needle-
shaped particles could be observed among a much finer fraction of particles (Figure 
11b). In contrast, RESS TP 3 consisted of homogeneous fine particles while no large 
micron-sized bundles as in RESS TP 2 were found (Figure 11c). At a higher 
magnification, it could be observed that the particle shape was rather anisometric, with 
long and thin, strongly agglomerated fibers (Figure 11d).  
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Measurement of the particle size via laser diffractometry revealed that unprocessed TP 
had a Dv90 of 208.7 ± 3.3 µm and a comparatively large span of 3.35 ± 0.01 (Table 4). 
The particle size reduction of RESS TP produced at the second temperature interval 
was about one order of magnitude compared to the unprocessed material, but the span 
was still rather large (24.7 ± 8.1 µm and 3.3 ± 0.6; Table 4). These results reflect the 
heterogeneous particle collective that was already observed in SEM images. The 
particle size of RESS TP 3 was distinctly smaller than both unprocessed TP and RESS 
TP 2 and was therefore measured by dynamic light scattering (Figure 12c). The 
particle size reduction of RESS TP 3 was about 2 orders of magnitude compared to the 
unprocessed material, while the span was also distinctly reduced (1.1 ± 0.3; Table 4). 
Because of the high aspect ratio of the particles, the results of the particle size 
measurement under-estimate the real particle size as shown by SEM images. 
Therefore, measurement of the BET surface area appears to be a better method to 
evaluate the effect of RESS micronization. Unprocessed TP had an average specific 
surface area of only 0.412 m2g-1, whereas for RESS TP 2, it was increased to 3.43 m2g-1 
and to 5.78 m2g-1 for RESS TP 3, which corresponds to a 14-fold increase. 
Table 4 Summary of particle characteristics and thermal properties of unprocessed and RESS 
theophylline 
Product Particle size (μm) Span A (m2/g) Ton (°C) ΔHf (J/g) 
D10 D50 D90 
Unprocessed 
TP 
10.6 ± 0.2 59.2 ± 0.9 
208.7 ± 
3.3 
3.4 ± 0.01 0.41 ± 0.02 
271.4 ± 
0.03 
158.0 ± 
0.03 
RESS TP 2 1.9 ± 0.5 6.9 ± 1.7 24.7 ± 8.1 3.3 ± 0.6 3.43 ± 0.50 270.5 ± 1.0 152.8 ± 8.0 
RESS TP 3 0.085 ± 
0.0004 
0.143 ± 
0.02 
0.248 ± 
0.07 
1.1 ± 0.3 5.78 ± 0.07 270.0 ± 1.0 151.0 ± 0.1 
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Figure 11 SEM images of a) unprocessed theophylline; b) RESS TP 2; c) & d) RESS TP3 
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Figure 12 Particle size distribution of a) unprocessed theophylline (µm); b) RESS theophylline 
produced at temperature interval 2 (μm); c) RESS theophylline produced at temperature 
interval 3 (nm). 
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Solid state analysis of RESS theophylline 
The melting temperature of unprocessed TP was 271.4 ± 0.03 °C. A slight depression 
of the melting temperature of RESS TP 2 and 3 was observed, but it was not significant 
(270.50 ± 0.98 °C and 270.0 ± 0.98 °C, respectively). In contrast, the heat of fusion of 
RESS TP 2 and RESS TP 3 was distinctly reduced in comparison to the unprocessed 
material (152.83 ± 7.95 J/g and 151.03 ± 0.12 J/g vs. 157.96 ± 0.03 J/g,. For RESS TP 2, 
the standard deviation was very high though, meaning that the batch-to-batch 
variability was much higher than in RESS TP 3. The reduction of the heat of fusion 
could be caused by a reduced crystallinity or by the reduced particle size in 
comparison to the bulk material. For a better understanding, PXRD measurements 
were performed for the bulk material and RESS TP 2. The PY of RESS TP 3 was not 
sufficient for PXRD analysis due to the fact that the mass flow through the nozzle 
needed to be reduced distinctly in order to remain inside the defined temperature 
range, which also lowered the throughput of the process (see Table 2). Diffractograms 
of RESS TP 2 had identical peaks in comparison to the unprocessed material, but with 
a strongly decreased intensity (Figure 13).  
 
Figure 13 Powder X-Ray Diffractograms of unprocessed TP and RESS TP 2 
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a) 
 
b) 
 
 
Figure 14 FTIR spectra of unprocessed theophylline and RESS theophylline; a) main stretching 
vibrations of functional groups (band assignments based on (73)); b) fingerprint region 
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No direct trace of amorphous material could be found. Many researchers report a 
reduction in the PXRD peak intensities of RESS precipitated material in comparison to 
the unprocessed bulk powder, but that could again be related to the decreased particle 
size of RESS products and is therefore inconclusive for judging a possible reduction of 
crystallinity (36, 39, 42, 45, 70, 74, 75). The question of whether the material contained 
an amorphous portion could therefore not be answered conclusively with the 
presented data.  
 No difference between unprocessed TP and RESS TP could be observed in 
FTIR spectra, neither in the vibrations of the functional groups (N-H stretching 
vibration at 3119 cm-1, C=O stretching vibration at 1718 cm-1 and 1667 cm-1 (73)) nor 
in the fingerprint region (Figure 14 a and b).In contrast to a previous study, no 
hydration of RESS TP could be observed (47). Hydrate formation is most probable to 
occur after the actual RESS experiment, in cases when the precipitated material is still 
at a low temperature due to Joule-Thompson cooling and removed from the 
expansion chamber too early, so that air moisture condensation leads to hydrate 
formation. More importantly, no solvate formation of RESS TP with remnant 
methanol could be observed. Judging by DSC, PXRD and FTIR results, it is most likely 
that RESS TP produced in this study was in the same solid state form as the 
unprocessed material, regardless of the temperature inside the expansion chamber.  
Conclusions 
Micronization of poorly soluble API's via RESS is the most important and so far also 
the most studied application of the technique, but many API's do not have sufficient 
solubility in scCO2. As this is a prerequisite for a compound to be processed with 
RESS, in this chapter, the development of a liquid cosolvent-assisted RESS process was 
described to overcome the problem of poor solubility in scCO2. With the addition of as 
little as 4 % wt. % methanol as organic cosolvent to the supercritical phase, the 
solubility of theophylline (TP) in scCO2 and thus the process yield could be increased 
CHAPTER 2 | Cosolvent-Assisted RESS Micronization 39 
from close to 0 % without cosolvent to 25 % with the addition of cosolvent. 
Micronization of TP with the described process was successful, since a 14-fold increase 
of the specific surface area could be achieved, while the particle size of RESS TP was 
distinctly reduced compared to the unprocessed material. It could be demonstrated 
that a careful control of the expansion conditions is vital to obtain a homogeneous 
particle size distribution when using a liquid cosolvent in the RESS process. If the 
liquid-vapor line of the binary mixture CO2 + methanol was crossed during the 
expansion, methanol was precipitated in liquid state.  
 At a very low temperature (0 - 5 °C), the precipitated liquid organic phase 
dissolved the particles entirely. With increasing temperature, this could be avoided so 
that a dry powder product was obtained. At an intermediate temperature interval (15 -
 30 °C), the formation of a liquid phase during the expansion process still had a 
distinct influence on particle morphology and the size distribution. Even though 
solvate formation was not observed, methanol in liquid state caused agglomeration, 
recrystallization and distinct particle growth of the product during its residence time 
in the expansion chamber. At a higher temperature (>30 °C), the formation of liquid 
methanol and thus agglomeration and recrystallization of the product could 
apparently be restricted, so that RESS TP produced at this temperature interval had a 
much smaller particle size, a higher specific surface area and a more homogeneous 
particle size distribution than RESS TP produced at the intermediate temperature 
interval.  
 The work presented in this chapter demonstrates that low solubility of many 
compounds in scCO2 does not necessarily need to be a major restriction for RESS, 
since small adaptions of the process can render a much wider range of materials 
applicable for RESS processing. 
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CHAPTER 3 | FORMATION OF NANOSUSPENSIONS WITH RESS  
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Introduction 
Drug nanocrystals and nanosuspensions are widely considered as an easy approach to 
overcome low solubility and bioavailability of poorly soluble drugs (76-80). 
Nanosuspensions are dispersions of drug particles with a size less than 1000 nm in an 
aqueous medium (78). Due to the large surface energy that promotes agglomeration, 
nucleation and/or particle growth, they are thermodynamically unstable. In the 
absence of appropriate stabilizers, flocculation and Ostwald ripening may thus impair 
their dissolution rate and in vivo performance. Stabilizers for nanosuspensions can 
basically be classified as steric or electrostatic (81). Non-ionic polymers confer steric 
repulsion, while ionic surfactants confer electrostatic repulsion to the particles. A 
combination approach is often chosen, because the mechanisms have a synergistic 
stabilizing effect and because steric stabilization alone is inherently more sensitive to 
temperature fluctuations, which can be a problem when the nanosuspension is 
subjected to temperature cycling e.g. during drying (77).  
 The advantages of nanosuspensions for drug delivery are the large surface area 
leading to a much faster dissolution rate and the increased saturation solubility of 
these formulations4 (77, 81). With nanosuspensions, it is possible to increase the drug 
loading, reproducibility of oral absorption and dose-bioavailability proportionality 
while decreasing toxicity and adverse effects (82). The formulation of nanosuspensions 
is especially suitable for compounds with a high log P, i.e. substances that are poorly 
                                                            
4 According to the Ostwald-Freundlich equation, the solubility is only affected, if very small 
particle sizes are reached: !(!)!!   =   𝑒𝑥𝑝 !!!!"#$!  !!!    
Where s(R) is the solubility of the material with a particle radius R, s0 is the solubility of the 
bulk material, γ is the interfacial tension, Vatom is the atomic volume, kB is the Boltzmann 
constant and T the temperature. With all other factors kept constant, the solubility s(R) 
increases with decreasing particle size. For s(R) to differ substantially from the bulk solubility 
(i.e. !(!)!!   >>   1); the exponential term needs to attain values higher than 1, which is only the 
case for particles in the nanometer range.
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soluble in water but soluble in oil (77). Olanzapine (OLZ) is a typical example of a BCS 
class II drug with poor solubility in water and high lipophilicity (Figure 15).  
 
Figure 15 Chemical structure of olanzapine 
  
As an antipsychotic drug, it binds to central dopamine D2 and serotonin 5HT2c 
receptors (83-85). In addition to its low aqueous solubility, OLZ shows pH dependent 
solubility because it is a weak base (pKa = 7.4; Table 5). To date, there are no reports in 
the literature about the formulation of nanosuspensions with OLZ. Only one study 
reports the formation of composite OLZ PLGA nanoparticles as a possible dosage 
form for parenteral administration of the drug (86). The reason for this is most 
probably the diversity of the compound's solid state forms. It has been reported that 
OLZ crystallizes in at least 25 different solid forms including polymorphs, hydrates 
and solvates5 (83, 87).  
 The formulation of OLZ as an aqueous nanosuspension is particularly 
challenging, because the most stable anhydrous OLZ form I converts within hours to 
the less soluble Dihydrate B in aqueous suspension (87).  
                                                            
5 In the present work, the nomenclature of OLZ forms is according to the one of Reutzel-Edens 
et al. (105). 
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The choice of stabilizer is therefore crucial to suppress recrystallization of the 
precipitated material to prevent particle growth and polymorphic conversion. 
Table 5 Summary of olanzapine properties 
Molecular Mass (g/mol) 312.44 
Melting point (°C) 195 
pKs (I) 7.4; (II) 14.17 
Solubility in water; mg/ml 0.03 
Solubility in scCO2 no literature available 
Log P 2 
  
 Nevertheless, there are a number of reasons why nanosuspensions can be a 
reasonable strategy for the formulation of OLZ dosage forms. First of all, 
nanosuspensions reduce food effects on the bioavailability of the drug when 
administered orally (77). In addition, the increased solubility of drugs formulated as 
nanosuspensions can reduce the administered dose. Even though OLZ is regarded as 
well tolerable, the high variability of oral bioavailability can lead to either sub-
therapeutic plasma levels or increased adverse affects (81, 88). Parenteral 
administration of OLZ is indicated in acute agitation of patients with schizophrenia or 
bipolar mania. The marketed formulation is a fast-acting intra-muscular injection of a 
solution with a low pH to achieve sufficient solubility of the OLZ base (88, 89). In 
comparison, nanosuspensions of OLZ could be administered as intravenous fast-
acting injection6 without the need of solubilizing agents or a non-physiological pH, 
                                                            
6 It is important that for intravenous administration the particles are smaller than 5 μm to avoid 
capillary blockage.  
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which often causes irritation and pain, especially with intra-muscular or subcutaneous 
injections.  
 Nanosuspensions can be either prepared by nanoprecipitation methods 
(bottom-up process) or by comminution of larger particles (top-down process). Top-
down processes include high-pressure homogenization or media milling. But the high 
shear forces used in these techniques can generate crystal defects and amorphous 
domains, which are then subjected to recrystallization throughout storage (82). Other 
problems are often a high polydispersity of the product, so that subsequent removal of 
microparticles is required, or the abrasion of milling equipment (76). 
Nanoprecipitation generally involves the use of organic solvents. This may have 
adverse effects on the final preparation because of the formation of unstable 
polymorphs, hydrates or solvates of the drug. In addition, complete removal of the 
solvents remains a challenge, so that physical and/or chemical instability and increased 
toxicity are possible consequences (82).  
 Another critical issue in conventional precipitation techniques is that the 
speed of precipitation needs to be maximized while the freshly created surface needs to 
be covered by surfactants quickly, so that growing of the crystals can be limited (80). 
In contrast, the high supersaturation that can be attained in RESS causes 
extraordinarily fast nucleation rates (see page 7). A comparable speed of precipitation 
cannot be attained in conventional nanoprecipitation methods. Considering that 
nanosuspensions are often regarded as the last resort when it comes to formulating 
insoluble drugs and that the conventional production techniques are to a certain 
extent unfavorable, the RESS process can offer a beneficial alternative production 
method. So in the case of water insoluble drugs, a supercritical solution of the 
respective solute can be directly sprayed into an aqueous solution containing a 
stabilizing agent. This technique has also been named RESOLV (Rapid Expansion of 
Supercritical Solutions into Liquid Solvent) or RESSAS (Rapid Expansion from 
Supercritical to Aqueous Solution) and has been tested on a lab scale for the 
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production of nanosuspensions with different pharmaceutical compounds and 
stabilizing agents (Table 6). When expanding the SCF into a liquid at the receiving end 
instead of air, particle condensation and coagulation in the expansion jet can 
apparently be quenched, because the products are often nanosized in contrast to those 
produced with the classic RESS process (90). Particle sizes in the range of 0.1 - 1 µm 
(90); but also less than 100 nm are generally reported (42, 48).  
 A difficulty in expanding a large amount of gas into a restricted volume of 
stabilizing medium is however that the expansion cooling causes a drastic temperature 
drop, so that the aqueous medium can freeze within a short time period. The force of 
the expanding gas can catapult the medium out of the collecting cylinder and foaming 
of the medium may destabilize the process. The process conditions thus need to be 
monitored very carefully in order to avoid these issues. Most of the available studies 
are focused on the influence of the production parameters, i.e. pre-expansion 
conditions and stabilizing agents, on the generated particle size and particle size 
distribution (Table 6). But solid state characterization of the drug in suspension, 
development of a valid drying method, analysis of the release characteristics and 
especially the stability of the nanosuspension are important issues that are often not 
included in RESS research. 
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Table 6 Literature examples of RESSAS/RESOLV applications for pharmaceuticals 
Substrates SCF Stabilizing agent Particle size Reference 
Salicylic acid scCO2 Polysorbate 80 180 nm Türk (2008) (40) 
Naproxen scCO2 Polysorbate 80 PVP 
8 µm 
0.56-0.8 µm Türk (2010) (41) 
PLA, Retinyl 
palmitate scCO2 Poloxamer; SLS 40 - 110 nm Sane (2009) (91) 
Fenofibrate scCO2 
Polysorbate 80, 
SLS, Poloxamer, 
HPMC 
 
0.5 - 5 µm Dalvi (2013) (44) 
Ibuprofen scCO2 SLS, PVP, PVA, PEG, BSA 25 - 276 nm 
Pathak (2006) 
(42) 
 
 The objective of this chapter is to evaluate if RESS nanosuspensions and their 
freeze-dried products are suitable as pharmaceutical dosage forms. To this end, a RESS 
process for producing nanosuspensions of OLZ was developed. Nanoparticles of OLZ 
were also produced with the classic RESS process to assess the influence of 
precipitation from supercritical solution on the stability and solid state of the drug. 
The nanosuspensions of OLZ were freeze-dried to improve handling and storage 
stability. The particle size was measured directly after production and after freeze-
drying to evaluate the effectiveness of the respective stabilizer. A solid state analysis via 
FTIR was included to assess the influence of the stabilizers on the polymorphism of 
the drug. Finally, the release characteristics of OLZ from freeze-dried nanosuspensions 
and the conventionally micronized drug product were compared, while the influence 
of the stabilizers on the drug dissolution rate was also taken into account. 
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Materials and Methods 
Materials 
Micronized olanzapine was obtained from Pharmogana, Rosenheim, Germany and 
carbon dioxide was purchased from Air liquide, Düsseldorf, Germany. 
Hydroxypropylmethylcellulose (Pharmacoat 615) was obtained from Syntapharm, 
Mühlheim a.d. Ruhr, Germany; PEG 40000 from Serva, Amstetten, Austria; 
polysorbate (Tween 80) from Croda, Nettetal, Germany and sodiumlaurylsulfate (SLS; 
Texapon K12G) from Cognis, Düsseldorf, Germany. 
Methods 
Solubility of olanzapine in supercritical carbon dioxide 
There are very few reports about supercritical fluid processing of OLZ in the literature. 
A US patent reports the production of OLZ form II with RESS, which is the only 
published solvent-based SCF technique to process OLZ (92). However, there is no 
solubility data included. The saturation solubility of Olanzapine (OLZ) in scCO2 was 
measured at 50 °C and 20 MPa or 30 MPa. At 20 MPa, the solubility was 
y = 8.67 x 10 6 mol fraction, which is comparatively low. At the chosen process 
conditions and with the used equipment, this equaled a dissolved mass of 241.5 ± 
4 mg. At 30 MPa, the solubility could be increased up to y = 2.15 x 10-5 mol fraction. 
Pilot studies that were conducted to optimize the process conditions for the 
production of nanosuspensions revealed that a pressure of 20 MPa was more suitable 
than 30 MPa, which is why a pressure of 20 MPa was chosen for all of the following 
experiments despite the lower solubility of the drug7. 
                                                            
7At 20 MPa, freezing and/or foaming of the receiving medium during the expansion process 
were easier to control; and at a lower concentration of the drug in scCO2, smaller particle sizes 
could be achieved. 
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Production of olanzapine nanoparticles with the RESS process 
The general description of the RESS equipment can be found in Chapter 2, page 24. 
1.5 g of the solid drug were placed inside the extraction chamber, which was 
consequently flooded with CO2, heated to 50 °C and pressurized to 30 MPa. After an 
equilibration time of 24 h, the solution was expanded during 60 min at a medium mass 
flow of 1.2 ± 0.4 kg/h CO2 (average of 3 RESS experiments), using the equipment 
presented in Figure 10 for particle collection. The heating mantle of the expansion 
chamber was set to 70 °C. The actual temperature inside the expansion chamber was 
monitored using the thermocouple T1 close to the nozzle exit (Figure 10). With the 
temperature drop, an average of 19.3 ± 9.5 °C (average of 3 RESS experiments) was 
maintained. Prior to particle collection, the expansion chamber was allowed to reach 
room temperature in order to prevent potential condensation of air moisture on the 
products.  
Production of olanzapine nanosuspensions with the RESS process 
The general description of the RESS equipment can be found in Chapter 2, page 24. 
5.0 g of OLZ were placed inside the extraction chamber, which was consequently 
heated to 50 °C and pressurized to 20 MPa. After 24 h of equilibration time, the 
solution was expanded into the expansion chamber during 60 min. The heating mantle 
of the expansion chamber was set to 55 °C. The temperature inside the expansion 
chamber was monitored via a thermocouple placed in the water bath surrounding the 
collection cylinder (Figure 16). The volume of stabilizer medium was 100 ml. The 
stabilizers were dissolved in phosphate buffer pH 7.4 in order to prevent a pH drift due 
to dissolved CO2 and consequent dissolution of OLZ in the medium. In cases when 
sodium lauryl sulfate (SLS) was added as co-stabilizer, 3.3 ml of a stock solution of 10 
wt. % SLS were added to 30 ml of the freshly produced nanosuspension. 
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Figure 16 Device in the 
expansion chamber used for 
particle collection in the 
production of nanosuspensions 
  
Determination of the olanzapine content in RESS nanosuspensions 
1 ml of the freshly produced nanosuspensions was diluted 1:100 in 0.1N HCl to 
dissolve the drug. The solutions were analyzed spectrophotometrically at 260 nm for 
the OLZ concentration cNS. It was ensured that at this dilution and the given 
wavelength, the stabilizing agents did not interfere with the OLZ absorption. 
Calculation of the RESS process yield  
For RESS nanoparticles, refer to the calculation presented in Chapter 2 (page 28). For 
RESS nanosuspensions, mE was calculated as the product of the OLZ concentration in 
nanosuspensions cNS and the final volume of the nanosuspensions VNS: 𝑚!   =    𝑐!" ∙   𝑉!"  Eq. 19 
 
The propagated error Δu for PY and mE was calculated as: ∆𝑢   = 𝑢    ∆!! ! + ∆!! !  Eq. 20 
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Lyophilization of RESS nanosuspensions 
3 ml of the nanosuspensions were transferred to 10 ml glass vials and pre-frozen at  
-18 °C for 24 h prior to freeze-drying. The nanosuspensions were lyophilized at -20 °C 
for 12 h, followed by a secondary drying phase of 12 h at 20 °C using a Lyovac GT2 
freeze-dryer (Finn-Aqua/GEA Pharma Systems, Hildesheim, Germany). 
Measurement of the viscosity of stabilizer media used in the production of 
RESS nanosuspensions 
The stabilizers were dissolved in demineralized water at the respective concentration 
and equilibrated at 37 °C for 30 min. The kinematic viscosity η was measured with a 
capillary viscometer according to Ubbelohde. The capillary constants were 
0.00314 mm2 s-2 and 0.02978 mm2 s-2. Each sample was measured in triplicate. 
Particle size measurement via Dynamic Light Scattering (DLS) 
The particle size and particle size distribution (PSD) of OLZ nanosuspensions were 
measured using a Zetasizer Nano ZS (Malvern, Herrenberg, Germany). 1 ml of the 
freshly produced or reconstituted RESS nanosuspensions was used. All samples were 
diluted 1:4 and equilibrated during 120 s at a cell temperature of 20 °C. Each sample 
was measured 3 times and the average values of 3 individual RESS batches are 
reported.  
Laser Diffractometry in aqueous dispersion 
This method was used for unprocessed OLZ and for RESS suspensions, where particle 
growth to the micron range was observed after freeze-drying and reconstitution. A 
Mastersizer 2000 (Malvern, Herrenberg, Germany) equipped with a Hydro 2000S 
sample dispersion unit was used. An amount of 10 mg of the unprocessed powder was 
suspended in demineralized water containing 0.1 % Polysorbate 80 to ensure a good 
dispersion of the hydrophobic OLZ particles.  
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The freeze-dried cakes of the RESS suspensions were re-dispersed with 3 ml of 
demineralized water. Prior to the measurements, ultrasound was applied to 
desagglomerate the particles during 60 s. 3 measurements were performed per sample 
and the average values of 3 individual RESS batches are reported. The span was 
calculated according to Eq. 18.  
Measurement of the zeta potential of RESS nanosuspensions 
A Zetasizer Nano ZS (Malvern, Herrenberg, Germany) was used. The samples were 
diluted 1:4 and equilibrated during 120 s at a cell temperature of 20 °C. Each sample 
was measured 5 times and the average values of 3 individual RESS batches are 
reported. 
Scanning Electron Microscopy (SEM) 
The equipment and procedure was described in Chapter 2 (page 29). 
Differential Scanning Calorimetry 
The equipment was previously described in Chapter 2 (page 30). The temperature 
range was 25 °C - 220 °C at a heating rate of 10 K. 
Fourier Transform Infrared Spectroscopy (FTIR) 
Measurements were performed using a Nicolet 380 FT-IR spectrometer in absorbance 
mode (Thermo scientific, Karlsruhe, Germany). A total of 30 scans was performed 
over a range of 4000-400 cm-1 at a scan speed of 0.5 cm/s. The second derivative of the 
FTIR spectra was calculated using the OMNIC software (Thermo scientific, Karlsruhe, 
Germany). Flocculated RESS suspensions were filtrated and the solid remnant was 
dried at room temperature for FTIR analysis. 
Determination of the saturation solubility in water 
An excess of OLZ powder (approximately 10 mg) was placed into 2 ml Eppendorf cups 
and 1 ml of the respective stabilizing medium was added. The cups were sealed and 
placed into a water bath at 37 °C shaking with 60 spm. After 48 h, the Eppendorf cups 
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were centrifugated at 13,400 rpm for 20 min and diluted in 0.1 N HCl. The 
concentrations of OLZ were determined with a UV microplate reader at 260 nm 
(Synergy HT, Biotek, Bad Friedrichshall, Germany). 
In vitro dissolution rate 
Dissolution studies were conducted with a Pharmatest PT-DT 7 (Hainburg, 
Germany). A paddle apparatus (USP apparatus 2) at 37.0 °C was used. The freeze-
dried cakes of OLZ nanosuspensions were reconstituted with 3 ml of the dissolution 
medium and immediately added to the dissolution vessels containing 500 ml of 
phosphate buffer pH 6.8. The rotation speed of the paddles was set to 50 rpm. Samples 
were drawn at preset time intervals and filtered through a 5 µm sintered filter. The 
removed sample volume was immediately replaced by fresh medium. The 
concentration of the samples was analyzed with a UV microplate reader at 260 nm 
(Synergy HT, Biotek, Bad Friedrichshall, Germany). 
Results & Discussion 
Production of RESS olanzapine nanoparticles 
Because of the described solid state diversity of OLZ, the influence of RESS 
precipitation on the solid state characteristics of the drug was assessed. The product in 
these experiments was a very fine powder; and a large fraction of it was thus removed 
with the outgas. Judging by SEM images, the particles had a round shape and appeared 
partly merged with a mean diameter of roughly 200 nm (Figure 17). This could be 
confirmed with particle size measurements via DLS, which yielded a mean particle size 
of 190 nm and a narrow span of 1.08 (Table 7). In contrast, the unprocessed OLZ 
powder had a D50 of 39.3 µm, meaning that a 200-fold reduction of the particle size 
could be achieved with RESS. 
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Figure 17 SEM images of RESS olanzapine nanoparticles 
 
Table 7 Particle size and thermal properties of RESS olanzapine (nm) and conventionally 
micronized olanzapine (µm). Average of 3 individual RESS batches 
Particle size RESS OLZ  (nm)a OLZ (μm)b 
D10 120 ± 2 13.0 ± 1.0 
D50 191 ± 10 39.3 ± 1.0 
D90 327 ± 40 86.3 ± 1.3 
Span 1.08 ± 0.15 1.87 ± 0.04 
Thermal Property RESS OLZ OLZ 
Ton (°C) 190.7 ± 1.1 194.3 ± 0.9 
Heat of fusion (J g-1) 120.0 ± 2.7 102.2 ± 6.3 
a particle size measured via Dynamic Light Scattering  
b particle size measured via Laser Diffraction 
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The melting temperature of RESS OLZ was distinctly reduced from 194.3 °C of the 
unprocessed material to 190.7 °C (Table 7). In addition, the heat of fusion was 
decreased from 120.0 J/g to 102.2 J/g, which might indicate a reduced crystallinity of 
the RESS product. To confirm this, the second derivative of the FTIR spectra of RESS 
OLZ were compared with crystalline anhydrous OLZ and amorphous OLZ in the 
range of 900 cm-1 to 1100 cm-1 (Figure 18). RESS OLZ spectra combined characteristic 
bands of both the crystalline anhydrous form I and the amorphous form. The band of 
amorphous OLZ at 998 cm-1 for example appeared in RESS OLZ spectra, as well as the 
sharp peak of the anhydrous form at 927 cm-1. This confirmed that the material was 
indeed partially precipitated in the amorphous form. Due to the speed of precipitation 
in RESS, the formation of an amorphous phase appears to be likely and has indeed 
been shown before8 (93).  
 Amorphous conversion is however not a particular issue for RESS, as it has 
been shown that the degree of crystallinity can vary widely depending on the specific 
method of production (79). OLZ was apparently not subjected to polymorphic 
conversion due to RESS processing, because according to FTIR and DSC analysis, the 
product was precipitated as OLZ form I (87). Polymorphic conversion during the 
RESS process has been shown before and is supposedly related to the processing 
conditions such as extraction and expansion pressure and temperature (45, 53, 74). In 
any case, the crystallization of form I is the preferred result, because it is the most 
                                                            
8 According to Ostwald's rule of stages, one would expect the less stable form to crystallize first 
from a solution, because its Gibbs free energy is closest to that of the parent phase (75). This 
intermediate phase does not have to be a metastable polymorph, but can also be the amorphous 
form. The following recrystallization to the more stable phase is not necessarily solution-
mediated, which would not be possible in the case of RESS, but can also occur via an internal 
rearrangement of the molecules (solid state transformation) (91). Because SEM, DSC and FTIR 
results suggested that the RESS OLZ nanoparticles were not entirely crystalline, it is possible 
that the material was precipitated in the amorphous state and then subjected to such a solid 
state transformation.  	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stable crystal form. Form II for example discolors in the presence of air, which makes 
it less suitable for commercial use (94). 
 
Figure 18 Second derivative of FTIR spectra of anhydrous, amorphous and RESS olanzapine. 
Dashed line indicates characteristic peak of the anhydrous crystalline form I; dotted lines 
indicate characteristic peaks of the amorphous form 
 
Optimization of process conditions for RESS nanosuspensions 
In RESS, a large amount of gaseous CO2 is formed during the expansion, which is 
particularly critical when the solute has a low solubility, so that the ratio of gas to 
product becomes very large. The expanding gas can lead to distinct foam formation 
and discharge of the receiving liquid, when it streams out of the collecting cylinder. In 
addition, the drastic Joule-Thompson cooling can freeze the aqueous medium, 
especially when the volume is already reduced. Pilot studies were thus conducted to 
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optimize the mass flow through the nozzle, the post-expansion temperature and the 
volume of the stabilizing media. The optimized conditions are presented in Table 7. 
Furthermore, the stabilizers were found to have a critical effect not only on the 
stability of the formulation but also on the expansion process. It was therefore also 
necessary to screen for suitable stabilizers. The 2 most important identified stabilizer 
features were viscosity and foaming tendency. The higher the viscosity, the less 
medium was discharged from the collection chamber. A high viscosity could be easily 
achieved with a variety of polymers in increasing concentrations.  
 But many polymers also distinctly increased the foaming tendency, so that e.g. 
many cellulose ethers were not feasible. Surfactants providing electro-static 
stabilization caused extreme foaming and fast depletion of the receiving liquid, so that 
they were also excluded. Beside the viscosity and foaming, the third important factor 
was the solubility of the drug in the stabilizing medium, which is crucial regardless of 
the production method. An increased solubility can induce agglomeration and/or 
Ostwald ripening (82). 
Table 8 Summary of process conditions for the production of OLZ nanosuspensions. (Average 
of 3 RESS experiments per stabilizer) 
Stabilizer 
Mass flow of CO2 
(kg/h) 
Temperature in 
expansion 
chamber (°C) 
Volume of 
stabilizing medium 
(ml) Polysorbate 80 0.1 % 1.55 ± 0.54 40.5 ± 2.3 100 
PEG 2 % 3.01 ± 0.34 39.2 ± 2.2 100 
HPMC 2 % 2.59 ± 0.77 41.9 ± 2.2 100 
 
The stabilizer should thus have little or no effect on the solubility of the formulated 
drug. The stabilizers that were chosen based on these selection criteria are presented in 
Table 9. Polysorbate 80 is a low-molecular weight non-ionic surfactant that has been 
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used widely in the formulation of nanosuspensions and, apart from stabilizing the 
system, helps as a wetting and dispersing agent with very hydrophobic drugs (95). PEG 
and HPMC are polymers that confer steric repulsion (82). None of these stabilizers 
increased the saturation solubility of OLZ in comparison to phosphate buffer pH 7.4 
(Table 9). In contrast to PEG, Polysorbate and HPMC caused foaming when CO2 
during the expansion.  
Table 9 Viscosity (η) of stabilizing media and saturation solubility (s) of olanzapine 
Stabilizer wt. %  stabilizer s (mg/ml) η (cSt) Foaming tendency 
Buffer pH 7.4 - 0.16 ± 0.06 0.81 ± 0.001 - 
Polysorbate 80 0.1 0.11 ± 0.003 0.72 ± 0.001 + 
PEG 2 0.16 ± 0.01 1.63 ± 0.001 - 
HPMC 2 0.16 ± 0.01 7.27 ± 0.005 + 
 
Production of RESS olanzapine nanosuspensions 
Nanosuspensions could be successfully produced with the 3 stabilizers HPMC, PEG 
and Polysorbate 80. But because of the foaming caused by HPMC and Polysorbate 80, 
the volume of the receiving liquid was decreased by more than 50 % by the end of the 
expansion process (Table 10). With PEG on the contrary, almost no foaming was 
observed, and it was possible to quantitatively recover the drug that was initially 
dissolved in scCO2, corresponding to a process yield of almost 100 % (Table 10). With 
an average concentration of about 3 mg/ml, the drug load was comparably low, given 
that with top-down techniques such as high-pressure homogenization or wet media 
milling, drug loads of at least one order of magnitude more can be achieved (96, 97). 
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But low drug loads are indeed a common problem for all bottom-up techniques, and 
not at all particular to the RESS process (82).  
Table 10 Quantitative analysis of RESS olanzapine nanosuspensions  
Stabilizer 
Volume of final 
suspension 
(VNS; ml)a 
c OLZ in final 
suspension 
(cNS; mg/ml)a 
Recovered mass 
of OLZ (mE; 
mg)b 
Process yield 
(PY; %)b 
Polysorbate 80  30 ± 11 3.3 ± 1.4 99 ± 55.5 41.0 ± 23.0 
PEG  70 ± 5 3.4 ± 0.4 238 ± 32.8 98.6 ± 13.6 
HPMC  45 ± 10 2.4 ± 1.3 108 ± 63.2 44.7 ± 26.2 
a: average ± standard deviation of 3 individual experiments; b: average ± absolute propagated 
uncertainty 
Stability of RESS olanzapine nanosuspensions 
The smallest particle size after production was achieved with Polysorbate 80 as 
stabilizing agent. The Di50 value was 158.7 ± 12.7 nm with a narrow PSD 
(span = 1.15 ± 0.12; Figure 19a). The largest particles were obtained with HPMC with 
a Di50 of 341.3 ± 42 nm and a broader PSD with a span of 1.5 ± 0.4 (Figure 19a). The 
particle size of PEG stabilized nanosuspensions was between that of Polysorbate 80 
and HPMC with a Di50 of 213.8 ± 23.7 nm and a narrow span of 0.99 ± 0.08 (Figure 
19a). After production, PEG and Polysorbate 80 nanosuspensions remained 
macroscopically stable for a couple of hours, until the transparent suspensions 
suddenly started to turn cloudy and agglomeration became visible quite rapidly. After 
freeze-drying and reconstitution of the PEG and Polysorbate 80 nanosuspensions, the 
particle sizes were measured again and indeed distinctly increased (Dv50 of 
8.5 ± 0.9 µm for PEG and 15.1 ± 2.6 µm for Polysorbate 80; Figure 19b). For both 
stabilizers, the PSD was also distinctly increased after freeze-drying. The particle size 
of OLZ in HPMC nanosuspensions was initially slightly larger than with the other 
stabilizers, but no visible particle growth was observed macroscopically during 24 h. 
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When measured again after freeze-drying, only a slight particle growth was detected 
(365.8 ± 72.3 nm after freeze-drying vs. 341.3 ± 42 nm before freeze-drying; Figure 
19b). This could be attributed to the higher viscosity of HPMC suspensions compared 
to PEG and Polysorbate 80, which reduced the diffusivity of the drug molecules in 
suspension (Table 9). 
 
Figure 19 Particle size, span and zetapotential (ZP) a) before and b) after freeze-drying (FD) 
and reconstitution of the RESS nanosuspensions. Error bars represent standard deviation of 3 
separately produced RESS batches 
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In bottom-up techniques, a fast adsorption process and slow desorption of the 
stabilizer molecules onto the freshly created drug surface are crucial to ensure fast and 
complete surface coverage of the precipitated nanoparticles and therefore a well 
stabilized system (77). If the drug particle surface is not covered fast enough, or if the 
interaction is of a weak nature, then agglomeration and particle growth are naturally 
observed after production. It has been argued that Polysorbate 80 as a small molecule 
size sometimes does not provide a very effective stabilization and co-stabilizers should 
be used in such cases (98).  
 In the case of PEG, the insufficient stabilization could be attributed to the 
molecular weight of the polymer, because its adsorption rate onto the drug surface 
decreases with increasing molecular weight of the steric stabilizer (96). Because the 
PEG derivative used here had a molecular weight of Mw ∼ 40,000, this could explain 
the insufficient stabilization. A derivative with a lower molecular weight might be a 
better choice regarding the stabilization, but would also mean a lower viscosity, which, 
as explained above, is a disadvantage during the production process. This shows that 
the choice of excipients can be somewhat limited and that it is vital to find a 
compromise between process operability and formulation stability when using RESS as 
a tool for the production of nanosuspensions. 
Effect of retro-active co-stabilization with SLS 
Because steric stabilization was not entirely effective, it was attempted to co-stabilize 
the OLZ nanosuspensions with sodium lauryl sulfate (SLS). SLS is an electrostatic 
stabilizer; it could thus not be added during the precipitation process due to the 
increased foaming tendency of the receiving liquid (see page 56). But since 
agglomeration of the particles was only observed a couple of hours after the actual 
production process, it was hypothesized that there is a time window for retrograde 
stabilization of the nanosuspensions. 
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Especially anionic surfactants like SLS are known to increase the saturation solubility 
of a large number of compounds, which can cause Ostwald ripening (99). Indeed, the 
saturation solubility of OLZ was increased to 0.8 ± 0.01 mg/ml in combination with 
PEG, and to 1.62 ± 0.2 mg/ml in combination with HPMC when 1 % m/V of SLS was 
used (Table 11). Because of the low average drug load, the attempt was only feasible for 
PEG stabilized nanosuspensions. With the addition of SLS to PEG stabilized 
nanosuspensions, the particle growth could be effectively suppressed, because only a 
slight increase of the particle size was measured after freeze-drying and reconstitution 
(Figure 19b). The addition of 1 % SLS resulted in a zeta potential of -33 mV, which 
reflects that the suspensions were indeed physically stable (80). 
Table 11 Saturation solubility s of OLZ in different stabilizing media with 1 % m/V of SLS 
Medium Saturation solubility s of OLZ with 1 % SLS (mg/ml) 
Phosphate buffer pH 7.4 1.82 ± 0.05 
Polysorbate 80 0.1 % n.a. 
PEG 2 % 0.8 ± 0.01 
HPMC 2 % 1.62 ± 0.2 
n.a. not analyzed 
It was suggested that production of nanosuspensions via RESS can be divided into two 
related processes, the first being the actual precipitation step and the second the 
stabilization of the initially formed particles (42). Although one would expect that if 
the co-stabilizer is not present at the actual precipitation process to immediately cover 
the freshly created surface, then the final particle size is not that of the initially 
precipitated particles (77). But with the addition of SLS immediately after production, 
the particle size of OLZ in PEG nanosuspensions was only slightly bigger than 
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nanoparticles produced with the classic RESS process (see page 53). It could thus be 
demonstrated that there is a time span after the actual production process in RESS that 
can be used for retroactive stabilization. 
Solid state characterization of olanzapine in nanosuspensions after freeze-
drying 
As explained in the introduction, OLZ tends to form a hydrate in aqueous suspension 
within a couple of hours (87). With second derivative FTIR, it is possible to enhance 
the resolution of overlapping and complex bands in original FTIR spectra. A range of 
the spectrum (950 - 1050 cm-1) was chosen, where the stabilizers did not interfere with 
the OLZ spectra (Figure 20). Hydration to the dihydrate B became apparent from two 
peak shifts of the anhydrous form at 965 cm-1 and 1009.6 cm-1 to 1003.8 cm-1 and 
971 cm-1, respectively (Figure 20). OLZ in the flocculated suspensions with PEG and 
Polysorbate 80 was completely transformed to the dihydrate B (Figure 20). After 
freeze-drying, the hydrated form was maintained by OLZ in PEG suspensions, while 
OLZ in Polysorbate 80 suspensions was dehydrated during the drying process so that 
the solid remnant again contained the anhydrous form I. Judging by the appearance of 
double bands in OLZ spectra of freeze-dried HPMC nanosuspensions, the drug was 
probably partially hydrated (Figure 20).  
 Only OLZ in freeze-dried nanosuspensions stabilized with PEG and SLS 
showed no trace of hydrate formation. This also became apparent macroscopically, 
because flocculated and hydrated OLZ turned white, while nanosuspensions stabilized 
with PEG and SLS appeared yellow and transparent after freeze-drying and 
reconstitution just like the freshly produced samples (Figure 21). 
 Particle growth and hydrate formation coincided in the insufficiently 
stabilized nanosuspensions. This is because the anhydrous form I is more soluble than 
the dihydrate B and thus, solvent-mediated recrystallization occurs (87). The 
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supersaturation will be higher with respect to the dihydrate B than to the anhydrate, 
because it is less soluble so that its nucleation rate will be higher (87, 100). 
 In previous studies, it was observed that the hydrate formation of 
carbamazepine could be suppressed by the addition of several polymeric excipients to 
suspensions of the drug (101, 102). Apparently, the polymeric agents stabilized smaller 
nuclei of the hydrate and prevented them from growing to the critical size, from where 
nucleation and particle growth start (see page 7). The interaction was ascribed to the 
H-bonding capacity of the polymeric agents with the drug and also the increase of 
viscosity caused by the excipients, which reduced the diffusivity of the drug molecules. 
Similarly in this study, HPMC strongly increased the viscosity of the medium, thus 
constraining the diffusivity of the drug molecules. The polymer has both hydrogen 
acceptor and donor groups in the ring structure, which could provide a strong 
interaction with the drug surface. PEG on the other hand caused only a slight increase 
of the viscosity and has only hydrogen bond donor groups at the end of the polymeric 
chains, while the hydrogen acceptor in the hydroxyl group is very weak. It therefore 
seems plausible that the protective effect of HPMC is more pronounced than that of 
PEG. Polysorbate 80, on the other hand, as a non-polymeric small molecule prevented 
neither particle growth nor hydrate formation.  
In vitro dissolution rate 
OLZ from RESS suspensions dissolved distinctly faster compared to the micronized 
powder reference, regardless of the drastic particle growth in Polysorbate 80 and PEG 
suspensions (Figure 22a). Since the stabilizing agents all possessed more or less 
pronounced surface activity, their influence on the dissolution rate of the reference 
material was also investigated (Figure 22b-d). Therefore, suspensions of the 
micronized drug powder in the respective stabilizing media were also tested. A distinct 
acceleration of the dissolution rate was observed for all stabilizing agents, which shows 
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that their effect cannot be underestimated. The effect of the size reduction was, 
however, still apparent in all RESS suspensions (Figure 22c). 
 
Figure 20 Second derivative FTIR spectroscopy of olanzapine (OLZ) in flocculated 
nanosuspensions (fl NS) or freeze-dried nanosuspensions (fd NS) with different stabilizing 
agents 
 
  
 66 
 
Figure 21 Comparison of nanosuspensions (NS) before and after freeze-drying (FD) with and 
without the addition of SLS 
 
 
Figure 22 Dissolution profiles in phosphate buffer pH 6.8, USP apparatus II (Paddle) 
a) Release profiles of freeze-dried RESS nanosuspensions (fd NS) and unprocessed olanzapine; 
b-d) Release profiles of unprocessed olanzapine suspensions with the respective stabilizing 
agent (REF) in comparison to freeze-dried RESS nanosuspensions (fd NS) 
CHAPTER 3 | Formation of Nanosuspensions with RESS 67 
Conclusions 
Conventional techniques for the production of nanoparticles and nanosuspensions 
often involve harsh processing conditions and/or the use of organic solvents, which 
can cause chemical or physical instability of the product. In this chapter, it could be 
demonstrated that nanosuspensions can be successfully prepared with the RESS 
process as an alternative solvent free production technique. The mean particle size of 
RESS olanzapine nanosuspensions ranged from 160 to 340 nm depending on the 
stabilizer and all suspensions had a narrow particle size distribution, while the drug 
could be preserved in the most stable polymorphic state. 
 It was found that during the expansion period, the post expansion temperature 
and the CO2 flux through the nozzle are crucial parameters to ensure successful 
precipitation of the solute into the stabilizing medium. If carefully controlled, freezing 
or discharge of the receiving liquid with the expanding gas could be avoided, so that a 
quantitative recovery of the dissolved material could be achieved. At the same time, 
the pilot equipment used for collection of nanoparticles in suspension introduced in 
this work still leaves ample room for optimization. For instance, an optical cell for in-
line monitoring of the expansion process can greatly speed up the process of defining 
suitable expansion conditions. Furthermore, an additional inert gas flow around the 
nozzle and the liquid surface could help to reduce excessive foaming. It is thus 
expected that the process efficiency can still be enhanced significantly. 
 An important finding in this chapter is that the choice of stabilizer has a 
critical influence on both the stability of the nanosuspensions and the expansion 
process itself. This is because excessive foaming of the receiving medium caused by 
some steric and all of the tested electrostatic stabilizers could cause depletion of the 
medium and disruption of the process. Polymeric stabilizers are therefore the better 
choice from a processing standpoint. But steric repulsion is often not a sufficient 
stabilizing mechanism for nanosuspensions. On the one hand, it is thus vital to find a 
compromise between process operability and formulation stability when using RESS as 
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a tool for the production of nanosuspensions. But on the other hand, it could be 
shown that retroactive electrostatic stabilization will still lead to preservation of the 
nanosized particles. Theoretically, it is thus possible to divide the process of 
precipitation and stabilization to disconnect the adverse effect of electrostatic 
stabilizers on the precipitation process. But whether this is a viable approach for other 
compounds remains to be tested. 
 OLZ from reconstituted RESS nanosuspensions showed a distinct increase of 
the dissolution rate in comparison to both the micronized drug powder and 
suspensions of the micronized drug powder in the respective stabilizing media. But the 
drug load of the RESS nanosuspensions was comparatively low. There are however a 
number of suggestions to be made how this could be improved in future work. Firstly, 
a supercritical solution could be expanded over various cycles into the same receiving 
medium to increase the final drug concentration (44). Furthermore, the volume of the 
stabilizer could be decreased in order to achieve higher final drug loads. In this study, 
the approach was not feasible because it increased the risk of ice formation around the 
nozzle due to Joule-Thompson cooling. This could however be effectively prevented 
with an additional nozzle heating. Finally, the solubility of OLZ in scCO2 was shown to 
be much higher with increased fluid density, so that a higher concentration of the drug 
in scCO2 can be achieved, which will also increase the final drug load of the 
nanosuspensions. 
 Considering the beneficial features of the RESS process like the mild process 
conditions and the absence of organic solvents, but especially the narrow particle size 
distributions and the small particle sizes, it is concluded that the RESS process may 
present a superior alternative to other bottom-up techniques for the production of 
pharmaceutical nanosuspensions; especially if the suggested developments of the 
equipment and collection device were to be realized. 
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CHAPTER 4 | FORMATION OF COCRYSTALS WITH RESS 
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Introduction 
Crystal engineering in the pharmaceutical sector traditionally encompasses hydrate 
and solvate formation, salt formation and polymorphic forms of crystalline API's. 
Cocrystallization in this field has emerged in the past 10 years as an alternative way of 
improving the physicochemical properties of pharmaceuticals; especially, if the 
respective drug is non-ionisable and thus salt formation is not possible (103-113). For 
a number of cocrystal systems, an increased dissolution rate could be observed, which 
makes cocrystallization an interesting additional tool for drugs with dissolution-
limited bioavailability (111, 114-117). The need for regulatory clarification of what is 
and what is not a cocrystal has been met recently by an issued draft guideline by the 
FDA, which reflects the growing importance of pharmaceutical cocrystals in industrial 
applications (104).  
 In cocrystals, an API and a structurally related additive are distributed 
homogeneously in a definite stoichiometric ratio and engage on a supramolecular level 
via non-ionic interactions (103, 104). If a cocrystal is composed of an acid and a base, 
the only difference between salt and cocrystal is the location of a proton (103, 113, 
118). To establish whether a compound should then be classified as cocrystal or salt, 
the FDA proposes to consider the following: If the API and the coformer have a ΔpKa 
of (pKa (base) - pKa (acid)) ≧  1, a substantial proton transfer will lead to ionization 
and salt formation. On the other hand, if ΔpKa is lower than 1, no substantial proton 
transfer will occur, so that API and coformer are present in unionized state and form a 
cocrystal rather than a salt (104).  
 Cocrystals are most commonly prepared by slow evaporation of organic 
solvent, or slow cooling from a solution of the cocrystal formers in organic solvent. 
But these production methods often do not lead to a pure cocrystal product, because 
there is always the risk of crystallizing the single components as a physical mixture 
(115, 119). To avoid this, experimental conditions need to be determined empirically, 
which often involves a lot of laboratory work, or knowledge of the ternary phase 
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diagrams of the cocrystal formers and the respective solvent is required (119). In 
addition, remaining residues of the solvents may contaminate the product. A 
production method that avoids this and invariably leads to the formation of cocrystals 
would therefore be desirable.  
 In this context, supercritical fluid assisted coprecipitation might provide 
crystallization conditions that suppress the segregation of the single components. 
Vemavarapu et al. first assessed RESS as a technique for crystal doping and 
coprecipitation of a large number of pharmaceuticals, and found that depending on 
the solubility and affinity of the components towards the supercritical solvent, 
cocrystal formation could be observed among other phenomena such as hydrate 
formation or polymorphic transition (47). The authors however found that 
supercritical solvent assisted cocrystallization was limited due to the fact that selective 
extraction of the components leads to inhomogeneous mixtures and thus incorrect 
stoichiometry of the supercritical solution. Selective extraction can occur, if one of the 
components presents a much higher solubility in scCO2 than the other, which was 
reported for theophylline and caffeine (47). Caffeine was found to exceed the solubility 
of theophylline by one order of magnitude, which will lead to a supercritical solution 
with according stoichiometry if the solids are presented in a 1:1 ratio (56).  
 In a different study, cocrystallization of indomethacin and saccharin was 
attempted via a supercritical solvent technique, which proved unsuccessful, since the 
solubility in scCO2 of both the pure components was too low (120). It is therefore most 
essential to consider the solubility limits of the cocrystal formers in scCO2 at the 
respective extraction conditions, since otherwise, the composition of the supercritical 
solution may not allow the formation of a pure cocrystal product. But this issue has so 
far not been addressed sufficiently in an experimental manner (47, 120).  
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Cocrystal precipitation via RESS compared to cocrystal precipitation from 
organic solvents 
Cocrystal precipitation from supercritical fluids differs from precipitation from 
organic solvents mainly in the speed with which the products are formed and the fact 
that in the RESS process, no equilibria between the crystallized solid product and the 
cocrystal formers in supercritical solution exist. In the RESS process, the precipitation 
of the solutes is irreversible, because after the expansion, the fluid returns to the 
gaseous state in which it has negligible solvent power (13). In contrast to this, for 
ternary systems of cocrystal formers in an organic solvent the equilibria between solid 
phase and the cocrystal formers in solution must be considered, since during slow 
evaporation of the solvent, the system may pass through several phase regions in the 
ternary phase diagram. This may result in precipitation of the cocrystal as well as of 
the pure coformer and the pure API (119). This again is dependent on the solubility 
limits of the cocrystal and the respective cocrystal formers.  
 As stated above, the solubility limits of the cocrystal formers in scCO2 are also 
important when considering RESS as an alternative way of cocrystal formation, 
because of the issue of selective extraction. But a large difference in solubility of the 
components in the supercritical solvent could also prohibit successful cocrystal 
precipitation because their precipitation is induced at different coordinates regarding 
the expansion path. As explained initially, the supersaturation S plays a fundamental 
role in the RESS process, because it is the driving force for nucleation and particle 
growth (22). A substance with higher solubility in the respective fluid undergoing the 
same expansion path as a substance with lower solubility will experience a different 
supersaturation rate. For the two solutes, particle nucleation will thus be theoretically 
initiated at different spatial or time coordinates regarding the expansion path (30). 
Nevertheless, a simultaneous precipitation of both components is plausible, if the 
affinity of the coformer is sufficiently high towards the host molecule in relation to the 
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solvent. A phase transition of the components would then coincide and dictate the 
nucleation and growth rate of the cocrystal (47).  
Model cocrystal of ibuprofen and nicotinamide  
The model API under investigation in this chapter is ibuprofen (IBU). IBU is a non-
steroidal anti-inflammatory drug used as analgesic in the short-term management of 
painful conditions and long term inflammatory conditions such as osteoarthritis (121). 
Especially in the first case, a fast absorption from the digestive tract is essential to 
ensure prompt and efficient pain relief. IBU however classifies as a BCS class II drug 
due to its low dissolution rate and aqueous solubility (Table 12). A 1:1 cocrystal 
structure of IBU and nicotinamide (NA) obtained by solvent evaporation and grinding 
has been previously described (115, 121, 122). This cocrystal could also be successfully 
prepared via hot melt extrusion (123, 124). The cocrystal assembly consists of a central 
NA amide dimer and linkages to carboxylic acid functions of IBU via the pyridine ring 
of NA (Figure 23) (122).  
 IBU has been shown to have a higher intrinsic dissolution rate from the 
cocrystal than the pure drug (115, 123). NA is the amine of nicotinic acid. It is a 
commonly used coformer in cocrystal architecture, since it has the structural 
prerequisites and is a non-toxic, FDA-approved additive (115, 121, 122, 125-127). In 
addition, NA has a well-studied hydrotropic effect and increases the apparent drug 
solubility via solution complexation (128, 129).  
 The IBU NA cocrystal is suitable as a model system for RESS processing, 
because both components show good solubility in scCO2, but they differ by at least one 
order of magnitude (14, 130) (Table 12). With the difference in solubility, selective 
extraction as well as separately induced nucleation of the components are issues that 
might prevent successful cocrystal formation via RESS. 
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Figure 23 Cocrystal assembly of ibuprofen and nicotinamide (122) 
The objective of this chapter is to investigate whether the RESS process is a beneficial 
alternative production method for cocrystals. In theory, RESS offers a one-step 
procedure for simultaneous cocrystal formation and micronization of the product. It is 
hypothesized that the additional micronization will lead to a better dissolution rate 
than cocrystals produced by the established solvent evaporation technique. But if RESS 
is to be used successfully for cocrystal formation, then both selective extraction and 
separately induced nucleation need to be prevented.  
 To test this, supercritical solutions of IBU and NA in different stoichiometric 
ratios were precipitated with the RESS technique to assess whether and how the 
stoichiometry of the supercritical solution could be controlled. Furthermore, the 
influence of the stoichiometry in supercritical solution on the formation of cocrystals 
was analyzed. The particle size, specific surface area and morphology were measured 
and compared to the unprocessed API powder. In addition, the pure API was 
micronized with RESS to assess the influence of the process on its particle 
characteristics and crystallinity. Finally, the dissolution rate was measured and the 
mean dissolution time was calculated as an indicator of improved dissolution 
performance. 
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Table 12 Summary of ibuprofen and nicotinamide properties 
Property Ibuprofen Nicotinamide 
Molecular Mass (g/mol) 206.29 122.12 
Melting point (°C) 76 128-131 
pKs 4.4 (I) 0.5; (II) 3.4 
Solubility in water; mg/ml 0.021 Freely soluble 
Solubility in scCO2; mol 
fraction; 40°C 
6.49 x 10-3 (22 MPa)(14) 7.5 x 10-4 (20 MPa) (130) 
Materials and Methods 
Materials 
Micronized R,S ibuprofen (IBU) with a median particle size (Dv50) of 50 μm was 
obtained from BASF, Ludwigshafen, Germany. Nicotinamide (NA) was purchased 
from Caelo, Bonn, Germany and carbon dioxide from Air liquide, Düsseldorf, 
Germany. Ethanol and Acetonitrile were purchased from Avantor, Deventor, The 
Netherlands.  
Methods 
Solubility of ibuprofen and nicotinamide in supercritical carbon dioxide 
For a general description of the procedure and the calculation calculation, refer to 
Chapter 2; page 28. IBU was freely soluble at the extraction conditions of 50 °C and 
30 MPa. Within a period of 3 h, 2 g of the compound were dissolved completely. NA 
on the contrary was not freely soluble at the given conditions and consequently 
dissolved much slower, so that the extraction time needed to be increased to 24 h. 
With a further increase of the extraction time, no significant enhancement of the 
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dissolved material could be achieved. The solubility of NA was thus y = 5.62 x 10-5 mol 
fraction9 . 
Micronization of ibuprofen and cocrystals with the RESS process 
For a general description of the RESS equipment and calculation of the RESS process 
yield, refer to Chapter 2, page 28. An accurately weighed amount of the solid material 
(see Table 13) was placed inside the extraction chamber, which was consequently 
flooded with CO2, heated to 50 °C and pressurized to 30 MPa. For the micronization of 
IBU, the equilibration time was 3 h. In all other experiments, the equilibration time 
was 24 h.  
Supercritical solutions of IBU and NA were prepared in 3 different stoichiometric 
compositions (Table 13). Since NA was less soluble than IBU, it was attempted to 
control selective extraction of IBU in the following manner: the amount of NA placed 
inside the extraction chamber and thus the dissolved fraction of the drug was kept 
constant in all experiments, while the amount of IBU was varied accordingly (Table 
13). After the respective equilibration time, the solution was expanded into the 
expansion chamber during 60 min, using the equipment presented in Figure 10 for 
particle collection.  
  
                                                            
9 The solubility measured here was much lower than the one found for NA in the literature 
(1.86 x 10-3 mol fraction (128)). This issue has already been discussed in Chapter 2. 
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Table 13 Summary of process conditions for the micronization of olanzapine, ibuprofen and 
coprecipitates (CP) of IBU and NA 
API 
Extraction 
time (h) 
Amount in 
extraction 
chamber (g) 
T in expansion 
chamber (°C) 
Mass flow of 
CO2 (kg/h) 
IBU 3 2.0 21.3 ± 0.9 2.98 ± 2.12 
RCC 0.5 : 1a 24 0.5 + 1.0b 18.3 ± 9.3 0.87 ± 0.57 
RCC 1 : 1a  24 1.0 + 1.0b 13.0 ± 1.3 0.89 ± 0.29 
RCC 2 : 1a 24 2.0 + 1.0b 14.7 ± 1.8 0.86 ± 0.59 
 
 
a intended molar ratio (IBU:NA) in supercritical solution and the products 
b m (IBU) + m (NA); IBU was freely soluble at the given extraction conditions (i.e. 100 % of the 
mass was dissolved), while only roughly 60 % of the mass were dissolved in the case of NA (i.e. 
∼0.6 g) 
 
To improve the particle yield, a suction pump was attached at the outlet and the 
expansion path was optimized for a shorter connection between the extraction 
chamber and the expansion chamber. Further details can be found in the Appendix. 
The heating mantle of the expansion chamber was set to 70 °C. The actual temperature 
inside the expansion chamber was monitored using thermocouple T1 close to the 
nozzle exit (Figure 10). Prior to particle collection, the expansion chamber was allowed 
to reach room temperature in order to prevent potential condensation of air moisture 
on the products.  
Preparation of cocrystals by slow solvent evaporation 
Cocrystals of IBU and NA in a molar ratio of 1:1 were prepared by slow solvent 
evaporation as a reference production method for cocrystals. Equimolar solutions of 
IBU and NA were prepared in ethanol (purity 96 %) and then joined in equal volumes 
into petri dishes. The solvent was left to evaporate slowly at ambient conditions during 
24 hours. The petri dishes were then placed into an oven at 30 °C for 6 hours to 
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remove the remaining solvent. Subsequently, the samples were triturated gently with a 
pestle and mortar and passed through a 250 µm sieve. 
Laser Diffractometry in dry dispersion 
A Mastersizer 2000 (Malvern, Herrenberg, Germany) equipped with a dry dispersion 
unit (Scirocco 2000) was used. The disperser pressure was set to 0.07 MPa. The span 
was calculated according to Eq. 18. 
Measurement of the specific surface area with the Brunauer-Emmet-Teller 
(BET) method 
The specific surface area was measured with nitrogen gas adsorption at -196 °C. The 
material was accurately weighed and analyzed with a SA 3100 Beckman Coulter 
system (Beckman Coulter, Krefeld, Germany).  The outgas temperature was set to 25 
°C at an outgas time of 180 min. The average results reported are those of 3 individual 
RESS batches. 
Scanning Electron Microscopy (SEM) 
The equipment and sample preparation was the same as described in Chapter 2, page 
29. In the case of RESS IBU and cocrystals, loose material recovered from the 
expansion chamber was used as samples. The material was fixed onto double-sided 
adhesive tape and otherwise prepared in the same fashion. 
Differential Scanning Calorimetry (DSC) 
The equipment used was described in Chapter 2, page 30. A heating rate of 25 °C to 
150 °C and a heating rate of 10 K/min was used for the measurement of melting points 
and specific heat of fusion of IBU, NA and cocrystals. The cocrystal yield α was 
calculated as 𝛼 = ∆!!∆!!!""%  Eq. 21 
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With ∆𝐻!!""%  as specific heat of fusion of the cocrystals prepared by solvent 
evaporation. 
Powder X-Ray Diffraction (PXRD)  
The equipment and procedure was described in Chapter 2 (page 30). 
Fourier Transform Infrared Spectroscopy (FTIR) 
The equipment and procedure was described in Chapter 2 (page 30). 
Confocal Raman Microscopy (CRM) and Imaging 
Raman spectra and color-coded images were obtained using an alpha 500R Raman 
microscope (WiTec, Ulm, Germany) equipped with a 532 nm excitation laser, UHTS 
300 spectrometer and a DV401-BV CCD camera. An area of 50 µm x 50 µm or 
30 µm x 30 µm was mapped using a 40x objective (numerical aperture 1.25). Color-
coded images were calculated after cosmic ray removal and baseline correction using 
the software WiTec Project Plus 2.10 (WiTec, Ulm, Germany). 
Measurement of dynamic contact angles with the modified Wilhelmy plate 
method 
The dynamic contact angles were determined using a tensiometer (K12, Krüss GmbH, 
Hamburg, Germany) with the modified Wilhelmy plate method (131). Adhesive tape 
was cut accurately to a length of 50 mm and a height of 20 mm, attached to a 
Wilhelmy plate and coated with the respective powders on both sides. Superfluous 
material was removed by gentle air pressure. The plate was suspended from an 
electronic microbalance and moved with a speed of 3 mm/min in and out of a test 
vessel containing demineralized water at 22.0 °C to a maximum immersion depth of 
5 mm. The contact angle θc was calculated according to 𝑐𝑜𝑠  𝜃!   =    !!"!!!!!∙!   
 
Eq. 22 
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Where Ftot is the measured vertical force (N), Fb is the buoyancy force (N), l is the 
wetted length (m), and σ is the surface tension of the test liquid (Jm-2). Fb was 
calculated with the laboratory desktop software 3.1. The wetted length was measured 
with a micrometer caliper for each measurement. The average values reported are 
those of 3 individual RESS batches. 
Determination of the equilibrium solubility in water 
The solubility of IBU as a pure drug, from physical mixtures and from RESS cocrystals 
was determined using a 48 h shake flask method in sealed 2.0 ml Eppendorf cups 
(132). 1.0 ml of demineralized water was added to the solids. To measure 
complexation between IBU and NA, known amounts of NA of increasing 
concentration were added to an excess of IBU (132). The cups were placed in a 
thermostated water bath at 25.0 °C and shaken at 60 spm for 48 h. Subsequently, the 
cups were centrifugated at 13,400 rpm for 20 minutes, the supernatant withdrawn and 
analyzed with HPLC (see below). The solid remnants of IBU NA physical mixtures 
and cocrystals were dried and analyzed with DSC to check for possible phase 
transitions. 
In vitro dissolution rate 
The in vitro dissolution rate was measured using a Stricker flow-through cell 
apparatus (Sartorius AG, Göttingen, Germany). Samples were placed into the rotating 
dissolution chamber together with 80 g of glass beads in 100 ml phosphate buffer pH 
6.4 (Ph. Eur.) at 37.0 °C. Samples of 3.5 ml were withdrawn at preset time intervals, 
filtered through a 0.2 µm cellulose nitrate filter and collected in test tubes. The 
removed sample volume was immediately replaced with fresh medium. For a detailed 
description of the calculation of the cumulative released mass with this apparatus, see 
(12). For a description of the validation procedure, see the Appendix.  
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The mean dissolution time (MDT) was calculated as 𝑀𝐷𝑇   =    !!!∆!!!!!! ∆!!!!!!     
 
Eq. 23 
Statistical evaluation of dissolution data 
The MDT values were compared using one-way analysis of variance (ANOVA) with a 
significance level of 95 % (p < 0.05) and the Scheffé test using SPSS statistics V22 
(Armonk, US). 
 
High Pressure Liquid Chromatography (HPLC) 
Concentrations of IBU and NA in aqueous solutions were measured with an HPLC 
system (LC 20AT, Shimadzu, Duisburg, Germany) equipped with a UV-detector 
(SPD-6A, Shimadzu, Duisburg, Germany) and a Nucleosil 100-5 C18 column 
(Macherey-Nagel, Düren, Germany). The detection wavelength was set to 230 nm. The 
mobile phase consisted of 60:40 (V/V) acetonitrile and 20 mM phosphoric acid pH 3.0 
at a flow rate of 1.0 ml/min. The injection volume was adjusted to 20 µl. 
Results & Discussion 
Process yield and quantitative composition of RESS coprecipitates 
RESS IBU and RESS coprecipitates could be produced with product yields of up to 
30 wt. % and 20 wt. %, respectively, in relation to the dissolved material. This 
corresponds to a comparatively high production rate of 0.4 to 0.6 g/h. RESS 
coprecipitates of IBU and NA were produced in 3 stoichiometric ratios, namely 0.5:1, 
1:1 and 2:1 (IBU:NA; Table 14). Quantitative analysis of the coprecipitates with HPLC 
revealed slight deviations of the actual molar composition of the products from the 
supercritical solution and from the intended composition, most distinctly in 
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coprecipitates with a molar ratio of 0.5:110 (IBU:NA). During the long extraction times, 
leakage of CO2 via fittings could cause a loss of pressure, which reduced the solubility 
of NA. The solubility of IBU was not susceptible to these changes because of its 
relatively higher saturation solubility in scCO2 (Table 14).  
 A shorter extraction time would make the problem of pressure fluctuation 
easier to handle. But then the speed of mass transport also needs to be increased 
efficiently, so that phase equilibria can be reached during shorter extraction times. 
This could for example be achieved with mechanic stirrers that intimately mix the 
solid and the supercritical phase inside the extraction chamber (130). Apart from the 
fluctuations of the NA concentration due to the equipment, selective extraction of IBU 
could be controlled successfully, so that an overall correct stoichiometric composition 
of the components in supercritical solution could be achieved. 
  
                                                            
10 For RCC 0.5:1, the molar fraction of IBU in supercritical solution was higher than in the 
products. This can be explicable by assuming that a portion of the API was lost because it 
crystallized separately. Judging by SEM images, pure IBU forms smaller particles than the 
cocrystal (Figure 29). It is thus possible that a small fraction of pure IBU was removed from the 
expansion chamber through the gas outlet, resulting in the observed shift of the molar 
composition of the products. Another possibility is that this part of the material was 
precipitated before the nozzle. In any case, the calculation of the concentration in supercritical 
solution is based on gravimetric measurement of the solid remnants, and is therefore not very 
accurate. 
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Table 14 Molar fraction of IBU in supercritical solution and in RESS products 
Sample Molar fraction of IBU in sc solutionb 
Molar fraction of IBU in 
productc 
RCC 1:1a 1.01 ± 0.09 0.94 ± 0.09 
RCC 0.5:1a 0.78 ± 0.09 0.56 ± 0.001 
RCC 2:1a 2.12 ± 0.4 2.05 ± 0.64 
a: Intended molar ratio (IBU:NA) in supercritical solution and products 
b: Measured by gravimetric evaluation of the remaining solid material in the extraction 
chamber 
c: Measured by HPLC 
Cocrystal identification in RESS coprecipitates 
To establish whether RESS coprecipitates consisted of a physical mixture of the 
cocrystal formers or if cocrystals were formed, different techniques of solid state 
characterization were used. As a reference, cocrystals produced by slow solvent 
evaporation (SCC 1:1) were used.  
Differential Scanning Calorimetry (DSC) 
DSC is a valid tool to establish whether cocrystal formation was successful, because the 
cocrystal of IBU and NA has a distinct melting point that is located between those of 
the single components (115, 121). RESS processing had no influence on the melting 
point of IBU, but a slight reduction of the heat of fusion was observed for RESS IBU in 
comparison to unprocessed IBU (Table 15). Reference cocrystals (SCC 1:1) exhibited a 
single sharp endotherm with an onset temperature of 90.6 ± 0.5 °C corresponding to 
the melting point of the cocrystal, which was in good agreement with the data reported 
in the literature (115, 121). A small trace of an impurity was repeatedly detected at 
∼64 °C, which probably corresponds to a eutectic of IBU and NA (Figure 24). 
Thermograms of RESS coprecipitates with a molar ratio of 1:1 (RCC 1:1) also 
exhibited a single melting peak with an onset temperature of 90.2 ± 0.4 °C, while the 
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melting points of the pure components were absent (Figure 24). Because RESS 
processing had no distinct influence on the heat of fusion of RESS IBU, it was assumed 
that the same holds true for RESS cocrystals. The heat of fusion was thus used as a 
quantitative readout for the cocrystal yield α of RESS cocrystals. For RCC 1:1, α was 
0.96 ± 0.07 (Table 15), which indicates that the starting material was almost 
completely transformed to cocrystals upon RESS precipitation. RESS coprecipitates 
with a molar ratio of 0.5:1 IBU:NA (RCC 0.5:1) also exhibited the cocrystal melting 
point, but at a slightly decreased temperature (89.8 ± 0.2 °C). Additionally, a second 
broad endotherm at roughly 105 °C was recorded. The latter probably corresponds to 
NA melting in the presence of the cocrystal, because a similar endothermic event was 
detected in a physical mixture of cocrystals and NA (Figure 24).  
 The cocrystal yield α was 0.69 ± 0.02, which indicates that the API was almost 
completely transformed to cocrystals11, while the superfluous amount of coformer 
crystallized separately. RESS coprecipitates with a molar ratio of 2:1 (RCC 2:1) showed 
two endothermic events. The first onset temperature was below those of the single 
components, which again probably corresponds to a eutectic of IBU and NA (65.3 °C 
vs. 75.0 °C for IBU and 128.6 °C for NA). The second endotherm had an onset 
temperature below that of the cocrystal (82 °C). Because these samples exhibited no 
clear evidence of cocrystal formation, they were excluded from further analysis. 
  
                                                            
11 With a molar ratio of 0.5:1 (IBU:NA), the maximum cocrystal yield is limited by the amount 
of API: m  (cocrystal)   =   0.5  mol  ×  M!(cocrystal) with M!(cocrystal)   =   328  g/mol. If the 
surplus of NA crystallizes separately, then the total product mass is given by: 
 m!"! =   m!"!#$%&'( +m!"#$%"!&'"()   =   0.5  mol  ×  328  g/mol   +   0.5  mol  ×  122  g/mol 
This means that at a stoichiometric ratio of 0.5:1, the maximum cocrystal yield with regard to 
the product mass can be calculated as α   =   !!"!#$%&'(!!"!   =   0.73 
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Table 15 Thermal key features of starting material and RESS products 
Sample Molar ratio IBU:NA Ton (°C) ΔHf (J g
-1) cocrystal yield α 
SCC 1:1 1:1 90.6 ± 0.5 133.2 ± 2.6 1 
RCC 1:1 1:1 90.2 ± 0.4 127.8 ± 10.4 0.96 ± 0.08 
RCC 0.5:1 0.5:1 89.8 ± 0.2 91.4 ± 3.3 0.69 ± 0.02 
RCC 2:1 2:1 65.2 ± 0.6 - - 
IBU  75.0 ± 0.3 124.1 ± 2.2  
RESS IBU  74.5 ± 0.7 120.3 ± 0.5  
NA  127.8 ± 0.1 192.2 ± 0.6  
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Figure 24 DSC Thermograms of ibuprofen (IBU), nicotinamide (NA), RESS coprecipitates 
(RCC), reference cocrystals (SCC 1:1) and a physical mixture of cocrystal and NA (pM SCC 
NA). Clear square marks the cocrystal melting peak; hatched square marks the endothermic 
event detected for melting of the cocrystal in the presence of NA 
Powder X-Ray Diffractometry (PXRD) 
The cocrystal of IBU and NA has an individual diffractogram that differs from those of 
the single components, which can be used to identify cocrystals and mixtures of 
cocrystals with the single components. Diffractograms of RCC 1:1 showed 
characteristic peaks at 9.41° and 12.55° 2θ, which were in good agreement with the 
reference cocrystals produced in this study (SCC 1:1) and the literature (122, 124) 
(Figure 25). The characteristic peaks of IBU (19.46° and 20.05 2θ) and NA (14.75° and 
27.25° 2θ) were absent in the diffraction patterns of RCC 1:1 (Figure 25). RCC 0.5:1 
exhibited the above-mentioned cocrystal peaks in addition to the NA peaks, but no 
pure IBU was detected. These findings are in good agreement with the DSC 
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measurements and support that IBU was fully transformed to cocrystals upon RESS 
precipitation, while, if a surplus of the coformer NA was present in the supercritical 
solution, it was precipitated separately. RCC 0.5:1 is therefore likely to be a physical 
mixture consisting of cocrystal and NA. The intensity of PXRD diffractograms of 
RESS products was distinctly reduced in comparison to reference cocrystals and the 
crystalline starting material. This could be caused by a reduction in crystallinity, but 
since there is no significant reduction of the melting peak, in this case it seems 
probable that the reduced intensity of the PXRD signals of RESS products is caused by 
the reduced particle size. 
 
 
Figure 25 PXRD diffractograms of ibuprofen (IBU), nicotinamide (NA), RESS coprecipitates 
(RCC) and reference cocrystals (SCC). Characteristic peaks of cocrystals (CC), NA and IBU are 
marked with dashed and dotted lines 
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Fourier Transform Infrared Spectroscopy (FTIR) 
In contrast to PXRD, RCC 1:1 and RCC 0.5:1 could not be clearly distinguished with 
FTIR, because the fingerprint region was nearly identical for these samples (Figure 26). 
Two broad peaks could be observed at 2459 and 1948 cm-1, which were attributed to 
hydrogen bonding between the carboxylic acid and the amine group of IBU and NA in 
the cocrystal assembly (dashed lines in Figure 26) (115). The δ NH2 vibration at 1620 
cm-1 was however more distinctive in RCC 0.5:1, which may indicate the presence of 
coformer not engaged in supramolecular hydrogen bonding. 
 
 
Figure 26 FTIR spectra of ibuprofen (IBU), nicotinamide (NA), RESS coprecipitates (RCC) 
and reference cocrystals (SCC); dashed lines mark hydrogen bonding and dotted line marks δ 
NH2 vibration 
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Confocal Raman Microscopy (CRM) 
CRM is a highly interesting technique for solid state analysis, because with color-
coded Raman imaging, the chemical information of the samples can be spatially 
resolved. This helps to identify crystals of the pure substances, cocrystals and/or mixed 
crystals. The prerequisite for this is that the spectra of the components differ in at least 
one of their characteristic peak positions. IBU and NA each exhibited such 
characteristic peaks and could be well distinguished (Figure 27). The characteristic 
peaks of IBU and NA in the Raman spectra at 1048 cm-1 (NA) and 1013.5 cm-1 (IBU) 
correspond to an aromatic ring deformation mode (Table 16; band assignments were 
based on previous studies (133-135)). The characteristic C-H stretching vibrations of 
IBU were located in the region of 2869 cm-1 to 2955 cm-1, and =C-H stretching 
vibrations were identified for both molecules at 3050 cm-1 (IBU) and at 3063 and 
3101 cm-1 (NA). NA also exhibited a weak N-H stretching mode at 3370 cm-1 and a 
NH2 deformation mode at 1620 cm-1. For both molecules, the O-H stretching vibration 
was a weak band located in the region of 3155 cm-1 (NA) and 3218 cm-1 (IBU).  
 The Raman spectra of cocrystals exhibited characteristic bands of both 
components (Table 16) and were equivalent for the RESS cocrystals (RCC 1:1) and 
reference cocrystals (SCC 1:1; Figure 27). The peak corresponding to the C=C 
deformation vibration was shifted from 1048 cm-1 in NA spectra to 1035 cm-1 in 
cocrystal spectra. This peak was used for imaging (highlighted in Figure 27a). Several 
peaks generated by structures involved in forming hydrogen bonds in the cocrystal 
were absent in cocrystal spectra, including the δ NH2 scissoring vibration and the ν N-
H stretching vibration of NA (Figure 27b &c). In addition, the bonds assigned to the 
C=O stretching vibration at 1680 cm-1 (NA) and at 1658 cm-1 (IBU) were shifted to 
1686 cm-1 in the cocrystal spectrum (Figure 27b). 
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Table 16 Main vibrational modes in the Raman spectra of IBU, NA and cocrystals (cm-1) 
Description NA Cocrystal IBU 
δ C=C 1048 1035 1013.5 
ν C-N 1397 1403 - 
ν C=C 1600 1612 1613 
δ NH2 1620 - - 
ν C=O 1680 1686 1658 
ν C-H - 2866; 2907; 2939 2869; 2920; 2955 
ν =C-H 3063; 3101 3050; 3079 3050 
ν OH 3155 3161 3218 
ν N-H 3370 - - 
ν: stretching; δ: deformation 
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Figure 27 a) Raman vibrational spectra of cocrystal samples and single components; peak 
positions used for imaging are highlighted; b) enlargement of δ NH2 vibration of nicotinamide 
(NA) at 1620 cm-1 (absent in cocrystal spectra) and ν C=O vibration region (ibuprofen (IBU): 
1658 cm-1 ; NA: 1680 cm-1; cocrystal (very weak): 1686 cm-1 ); c) enlargement of ν NH2 vibration 
of NA at 3370 cm-1 (absent in cocrystal) 
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In Raman image scans, a sample area is scanned and a spectrum is recorded for every 
pixel of the image. From these data, the distribution of the material in the sample can 
be calculated according to the spectral information. The resulting color-coded images 
of the samples contain the spatially resolved chemical information of the sample. With 
this technique, it is thus possible to obtain more accurate information about the 
distribution of the pure components and cocrystals throughout the RESS products. In 
image scans of physical mixtures, the single components and cocrystals could be well 
distinguished from each other (Figure 28). Raman imaging could thus be used as a tool 
to detect phase impurities in cocrystal samples, which is shown in Figure 28c and d; 
where image scans of RCC 0.5:1 are depicted. In these samples, cocrystals were 
detected in addition to separate NA crystals while no single IBU crystals could be 
found. 
 DSC, PXRD, FTIR and CRM all confirmed that a pure cocrystal phase was 
precipitated from supercritical solution, if the cocrystal formers were present in the 
correct stoichiometric ratio. But also with a surplus of coformer, the API was fully 
transformed to cocrystals. This shows that indeed the individual nucleation rates are 
not the determining factors dictating the precipitation, but that the affinity of the 
coformers towards each other causes a simultaneous precipitation and subsequent 
particle growth. 
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Figure 28 Raman image scans; color code: red: ibuprofen; blue: cocrystal; green: nicotinamide 
(a) Physical mixture of unprocessed ibuprofen and nicotinamide; (b) Physical mixture of RESS 
ibuprofen and RCC 1:1; (c) RCC 0.5:1; top color layer: cocrystal; d) RCC 0.5:1; top color layer: 
nicotinamide 
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Particle size and morphology of the starting material and RESS products 
SEM images revealed that the particle size of RESS IBU was distinctly reduced in 
comparison to the starting material (Figure 29a-d). The particles were strongly 
agglomerated and anisometrical. They also seemed partly molten and fused at the 
edges (Figure 29c). This may have been caused by the mantle temperature in the 
expansion chamber, which compensates the cooling in the immediate expansion zone 
but might provoke partial melting of the downstream deposited material. RESS 
cocrystals did not show this, which is most probably related to their higher thermal 
stability (90.2 °C). RESS cocrystals exhibited a noticeably different morphology 
compared to the starting material, since they precipitated as fibers with a high aspect 
ratio (Figure 29g). Furthermore, the particle size distribution of RESS cocrystals was 
comparatively large due to fiber-shaped particles that distinctly exceeded 10 µm. The 
same morphology was also observed in coprecipitates with a different molar ratio 
(data not shown). In contrast, IBU crystals were rather compact, while NA particles 
were porous and consisted of agglomerated and partly fused single crystals (Figure 
29a; e; f).  
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Figure 29 SEM images of a) & b) ibuprofen; c) & d) RESS IBU; e) & f) nicotinamide; g) RCC 
1:1; h) equimolar physical mixture of ibuprofen and nicotinamide 
 
The median particle size (Dv50) of RESS IBU and RESS cocrystals measured by laser 
diffraction was 9.0 ± 1.6 µm and 16.7 ± 0.7 µm, respectively (Table 17). These values 
are however equivalent diameters, because the high agglomeration tendency of the 
RESS material may have prevented a proper dispersion of the primary particles and 
the anisometric nature of the particles is not ideal for laser diffraction measurements, 
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since the algorithms for calculation of size from diffraction patters are based on a 
spherical particle shape. A better quantitative parameter for the size reduction is 
therefore the specific surface area as measured by BET. The specific surface area of 
RESS IBU was increased 4-fold in comparison to unprocessed IBU, while RESS 
cocrystals exhibited an almost 10-fold increase (Table 17). Because of the slow 
crystallization process, cocrystals produced by slow solvent evaporation (SCC 1:1) 
tended to form crystals with a large size distribution (Table 17). 
Table 17 Summary of median particle size (Dv50) , span, specific surface area (A) and contact 
angle θC 
Sample Dv50 (μm) Span A (m2 g-1) θC (°) 
IBU 49.6 ± 0.4 1.87 0.31 ± 0.01 80.5 ± 1.7 
NA 123.8 ± 2.5 1.25 1.14 ± 0.01 66.9 ± 5.3 
RESS IBU 9.0 ± 1.6 4.51 1.38 ± 0.08 91.0 ± 2.0 
SCC 1:1 39.9 ± 0.7 6.53 0.41 ± 0.02 84.4 ± 0.9 
RCC 1:1 16.7 ± 0.7 2.86 2.89 ± 0.22 87.8 ± 1.1 
 
Wetting properties and apparent solubility of RESS products 
In previous studies, many hydrophobic compounds have been successfully micronized 
via RESS, but quite often, the increase in dissolution rate was not as high as expected 
from the increase in specific surface area, or no increase could be observed at all (136). 
This was attributed to re-agglomeration and poor wettability of the RESS material. For 
this reason, the contact angle of water was measured with the modified Wilhelmy 
plate. RESS products apparently also had a slightly increased hydrophobicity, as 
indicated by an increased contact angle (Table 17). For RESS IBU, it was distinctly 
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increased to 91.0° ± 2.0° compared to unprocessed IBU (80.5° ± 1.7; Table 17). RESS 
cocrystals exhibited a similar value (87.8° ± 1.1°). Surprisingly, the same tendency was 
observed for cocrystals produced by slow solvent evaporation, but the effect was less 
pronounced (84.4° ± 0.9°). However, it is important to note that cocrystals did not 
exhibit a better wettability than pure IBU, regardless of the production method and 
despite the presence of the much more hydrophilic coformer NA in the host matrix. 
The increased contact angle may be the cause for the reduced equilibrium solubility of 
RESS IBU (0.277 ± 0.001 mM vs. 0.298 ± 0.049 mM for unprocessed IBU; Table 18). 
 A linear increase of the apparent solubility of IBU was observed with 
increasing NA concentrations in physical mixtures of IBU and NA. This was expected 
because NA is known to act as a hydrotrope for a variety of substances (115, 128, 129). 
The apparent solubility of IBU from RESS cocrystals was increased in the same order 
as observed for physical mixtures and corresponded to the concentration of NA 
present in the respective solutions (Table 18). DSC analysis of the undissolved solid 
remnants proved that they consisted of undissolved IBU with a minor trace of eutectic 
impurity (Figure 30). NA was thus completely dissolved from cocrystals, which 
indicates dissociation of the cocrystal upon dissolving (115).  
Table 18 Equilibrium solubility (mM) of IBU from physical mixtures (pM) and RESS cocrystals 
in dependence of the NA concentration 
Sample NA concentration (mM) 
0 SD* 20 SD* 30 SD* 40 SD* 
RESS IBU 0.277 0.001 -  -  -  
Physical Mixture 0.298 0.049 0.9122 0.091 0.992 0.097 1.116 0.097 
RESS cocrystals - - 0.863 0.145 0.993 0.043 1.065 0.062 
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Figure 30 DSC analysis of solid undissolved remnants from equilibrium solubility studies 
In vitro dissolution rate 
To assess whether RESS micronization had an additional impact on the dissolution 
rate of IBU from cocrystals, powder dissolution studies with the Stricker flow-through 
cell apparatus were performed. The dissolution rate of cocrystals was distinctly 
increased for both production methods, which is in agreement with previous studies 
(115). The observed increase was however greater for RESS cocrystals (Figure 31b). 
Calculation of the mean dissolution time (MDT) and statistical analysis revealed that 
the MDT of IBU from RESS cocrystals was significantly decreased (p < 0.05) to almost 
the order of the faster dissolving co-former NA (Table 19). RESS micronization 
therefore had an additional positive effect on the dissolution rate of IBU from 
cocrystals. The dissolution rate of RESS IBU on the contrary was decreased despite the 
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larger specific surface area (Table 17). This is probably attributed to the poor 
wettability of the material as shown by the contact angle measurements. This was 
already observed in a previous study for RESS IBU, where a much slower dissolution 
rate was obtained for the RESS product in comparison to the unprocessed material 
(137). It is therefore likely that RESS processing increases the surface hydrophobicity 
of the material to a certain extent. This could of course have diminished the observed 
effect on the dissolution rate of IBU from RESS cocrystals. 
Table 19 Mean Dissolution Time (MDT; min) of ibuprofen (IBU) and nicotinamide (NA) 
from different formulations  
 Unprocessed SCC 1:1 RCC 1:1 pM* 
IBU 10.9 ± 1.0a;b 10.0 ± 1.1b 6.2 ± 0.6c 13.3 ± 1.4a 
NA 4.8 ± 0.3a 7.7 ± 0.6b 4.6 ± 0.8a 8.1 ± 1.2b 
*pM = physical mixture; Values with different letters a-c in a row are significantly different at p 
< 0.05 (Scheffé Test) 
 
 The MDT of NA from cocrystals produced by solvent evaporation was 
increased in comparison to free NA (Table 19). This reflects the entrapment of NA in 
the host matrix of less soluble IBU molecules. Due to the overall larger surface area 
available for dissolution in RESS cocrystals, the MDT of NA from cocrystals was in the 
same range as NA alone. Surprisingly, the MDT of NA from equimolar physical 
mixtures was significantly increased (p < 0.05) compared to NA alone. This might be 
explained by an adsorption of IBU on the surface of NA particles, which could be 
observed by SEM images of dry physical mixtures of the 2 components (Figure 29b; f; 
h). In any case, this shows that the mere presence of the hydrotrope NA does not 
increase the dissolution rate of IBU, but that cocrystallization is indeed a prerequisite 
(123).  
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Figure 31 Comparison of in vitro dissolution profiles from different formulations of a) 
nicotinamide; b) ibuprofen. pM = physical mixture; RCC = RESS cocrystals; SCC = Cocrystals 
produced by slow solvent evaporation. 
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Conclusions 
Cocrystal formation can provide a successful strategy to improve the apparent 
solubility and dissolution rate of poorly soluble API's. Cocrystals are however often 
prepared via solvent evaporation techniques, which bear the disadvantage of 
crystallizing a mixed solid phase, while the products may be contaminated with 
remnant solvents. In this chapter, it could be demonstrated that RESS is a promising 
alternative production method for the formation and micronization of pharmaceutical 
cocrystals.  
 Selective extraction of the coformer with higher solubility in scCO2 could be 
controlled, so that the stoichiometric composition of the supercritical solution could 
effectively be tailored. This was important, because it was observed that precipitation 
of the cocrystal mainly depended on the molar composition of the cocrystal formers in 
supercritical solution. With a surplus of coformer dissolved in scCO2, the API was 
almost completely precipitated as cocrystals, while the excess coformer precipitated 
separately. With a surplus of API on the other hand, a mixed solid phase was 
precipitated, in which the cocrystal could not be clearly identified. The precipitation of 
a supercritical solution with the molar ratio of 1:1 led to the formation of a remarkably 
pure cocrystal phase. This can often not be achieved with conventional cocrystal 
production techniques, because during the evaporation of the organic solvent, the 
system passes through several phases of the ternary phase diagram. In RESS, on the 
contrary, the equilibria between dissolved and undissolved phase need not be 
considered, because the precipitation step is irreversible.  
 Due to the optimized expansion path and the additional suction pump 
attached at the outlet of the expansion chamber, a comparatively high process yield of 
20 - 30 % in relation to the dissolved material could be achieved.  
 RESS cocrystals had a distinctly increased specific surface area, which 
effectively led to a better dissolution performance in comparison to cocrystals 
produced by slow solvent evaporation. The particle morphology on the other hand was 
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not ideal, because an anisometric particle shape may negatively affect flowability and 
trigger demixing tendencies in powder mixtures. It has however been shown that the 
RESS process conditions can have a distinct impact on both particle size and 
morphology (46, 74). It is therefore expected that an optimization of the pre-
expansion temperature, pressure and the post-expansion conditions offers ample 
room for improvement in the matter of particle size and morphology. With RESS 
being a solvent free one-step procedure for cocrystal formation and micronization, 
further drying and size reduction steps can be dispensed. The most important 
advantage of RESS can however be seen in the high product purity of cocrystals, which 
clearly distinguishes RESS from organic solvent-based production techniques. RESS 
can thus present a valuable additional tool for crystal engineering of poorly soluble 
API's. 
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Summary 
An increasing number of newly developed pharmaceutical compounds are classified as 
poorly soluble according to the Biopharmaceutics Classification System (BCS). At the 
same time, many of the established processing techniques in pharmaceutical 
technology for enhancement of drug dissolution and solubility suffer from drawbacks 
arising from harsh process conditions such as high temperature, mechanical stress and 
the use of organic solvents. The Rapid Expansion of Supercritical Solutions (RESS) is 
an alternative processing technique for particle design and crystal engineering. In 
contrast to many established pharmaceutical processing techniques, RESS uses little or 
no organic solvents that can contaminate the products and raise their toxic potential 
or cause physical and chemical instabilities. The absence of organic solvents 
furthermore makes RESS a green technology, which is a growing demand of today's 
environment that is increasingly focused on sustainability. Finally, RESS avoids harsh 
processing conditions such as heat and mechanical forces that can negatively affect the 
crystallinity and polymorphic state of sensitive material.  
 The aim of this thesis was therefore to investigate the potential of RESS as an 
alternative technique for crystal engineering and particle design to improve aqueous 
solubility and dissolution of poorly soluble drugs. To this end, three applications of 
RESS were developed for dissolution rate and solubility enhancement in the fields of 
micronization, nanotechnology and crystal engineering.  
 In Chapter 2, a process for liquid cosolvent-assisted RESS micronization was 
developed in order to overcome the issue of poor drug solubility in supercritical 
carbon dioxide. It could be shown that with the addition of 4 wt. % of methanol to the 
supercritical phase, the solubility of theophylline could be increased by almost a factor 
of 25, while the process yield of RESS theophylline could be increased from around 
0 % to 25 %.  
 Theophylline could be successfully micronized with RESS as shown by a 14-
fold increase of the specific surface area. With increasing expansion temperatures, the 
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precipitation of methanol in liquid state could be suppressed so that recrystallization 
and agglomeration of the product could be minimized, while no solvent 
contamination or distinct reduction of the crystallinity could be detected in the 
product. This development of the classic RESS process could thus render a large 
variety of compounds applicable for RESS micronization and overcome what is 
generally considered a major restriction of the technique.  
 In Chapter 3, a process for the production of RESS nanoparticles and 
nanosuspensions of olanzapine, a poorly soluble BCS class II compound, was 
developed. With RESS, nanoparticles and nanosuspensions of olanzapine with a 
medium particle size of 160-340 nm and a narrow size distribution could be produced, 
while no polymorphic conversion of the drug was caused by RESS. Depending on the 
stabilizer, almost 100 % of the dissolved API could be recovered in nanosuspensions. 
The process parameters such as expansion temperature and CO2 flux through the 
nozzle were found to be critical for the successful production of RESS 
nanosuspensions, because freezing or discharge of the receiving liquid with the 
expanding gas could disrupt the process.  
 Polymeric stabilizers were found to be the better choice from a processing 
standpoint in comparison to ionic surfactants, because they caused less foaming and 
an increased viscosity of the stabilizing medium, which was beneficial during the 
expansion process. But the steric repulsion conveyed by polymers is often not a 
sufficient stabilizing mechanism for nanosuspensions. On the one hand, it is thus vital 
to find a compromise between process operability and formulation stability when 
using RESS as a tool for the production of nanosuspensions. But on the other hand, it 
could be shown that retroactive electrostatic stabilization will still lead to preservation 
of the nanosized particles in the suspension.  
 Finally, reconstituted RESS nanosuspensions showed a distinct increase of the 
olanzapine release rate in comparison to the reference material. Considering the 
absence of organic solvents, the mild process conditions and the high process yield 
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that can be achieved, production of nanosuspensions via RESS may represent a 
superior alternative to established bottom-up techniques for the production of 
nanosuspensions. 
 In Chapter 4, RESS was investigated as a tool for crystal engineering; namely 
the simultaneous formation and micronization of ibuprofen-nicotinamide cocrystals. 
Different molar ratios of the cocrystal formers were precipitated from supercritical 
solution and it was found that with an excess of coformer, the API was nearly 
completely precipitated as cocrystals while the excess coformer crystallized separately. 
With a surplus of API on the other hand, a mixed solid phase was precipitated, in 
which the cocrystal could not be clearly identified. A cocrystalline phase with 
remarkable purity was obtained when precipitating the cocrystal formers from a 
supercritical solution with the molar ratio of 1:1.  
 RESS cocrystals had a distinctly increased specific surface area, which 
effectively led to a better dissolution rate in comparison to cocrystals produced by a 
conventional solvent evaporation technique. The high product purity and the fact that 
cocrystals can be formed and micronized in a one-step procedure make RESS a 
promising alternative for conventional organic solvent-based production techniques.  
Concluding remarks and perspectives 
Rapid Expansion of Supercritical Solutions (RESS) is a promising and versatile 
technology for crystal engineering and particle design of poorly soluble drug 
molecules. Although RESS processing bears a number of immanent advantages over 
established pharmaceutical processing techniques, many applications of RESS are still 
on an experimental level and no commercial use for drug products is presently made 
of it. One of the critical issues related to RESS is the low process yield due to 
insufficient particle separation from the gaseous stream after expansion and the low 
solubility of many compounds in scCO2. As a consequence, RESS process yields of less 
than 5 % are commonly reported in the literature. In contrast to this, it could be shown 
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in Chapter 3 that the right choice of stabilizer and careful control of the expansion 
conditions in the production of nanosuspensions increase the process yield up to 
almost 100 %. In Chapter 2, due to the use of very low amounts of liquid cosolvent, 
the process yield of RESS micronization could be significantly improved from 0 % to 
around 25 % without negatively impacting the crystallinity or precipitating solvates of 
the model compound with the employed solvent. In Chapter 4, a process yield of 20 - 
30 % could be achieved in the precipitation of the model API and its cocrystal by 
mechanical improvements of the expansion path and the collection device. Even 
though these figures are still not ideal, this work shows that effective measures can be 
taken towards improved process yields. Considering the easy recycling of the 
expanded gas, an additional possible approach is the design of a continuous RESS 
process, so that low solubility and thus a lower throughput can be circumvented by a 
closed loop technology or even an array of nozzles. 
 Critical reports related to RESS often claim poor control over the particle size, 
morphology and size distribution. Indeed, the cocrystals produced in Chapter 4 had 
an anisometric needle-shaped morphology and a broad particle size distribution, so 
that further optimization of the process conditions is clearly necessary at this point. 
On the contrary, the nanoparticles and nanosuspensions of olanzapine produced with 
RESS in Chapter 3 had a highly homogeneous particle size and a very narrow size 
distribution. In Chapter 2, it could be shown that by simple modification of the post 
expansion temperature, the particle size, size distribution and specific surface area 
could be significantly improved. So there clearly is a dependence of particle size and 
morphology on both the material type and the RESS process conditions, and further 
research should address as to how the process conditions can effectively tailor particle 
morphology.  
 The RESS process probably bears the highest resemblance to spray drying 
when considering efficient particle collection and the concern regarding the product 
particle characteristics. Although spray drying is a well established technique and has 
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long been a common tool in the food and pharmaceutical industry, its history of more 
than 150 years of intense research concerning the optimization of atomization, 
flowability of the products and process efficiency is still ongoing. The immense 
research effort made in the field of spray drying and the significantly improved output 
that was consequently achieved may help to place the comparatively short history of 
RESS and the improvements shown in this thesis in a wider perspective. Specifically 
the issue of low process yields will require further scientific attention from a process-
engineering perspective. But from a pharmaceutical standpoint, it can be concluded 
that with the successful applications shown in the field of micronization, 
nanotechnology and crystal engineering, RESS offers a highly interesting and valuable 
technology platform with an up-to-date unexploited potential for particle design of 
poorly soluble drug molecules. At the same time, an increasing number of newly 
developed pharmaceutical compounds are classified as poorly soluble and the stability 
issues that arise from the use of organic solvents and rough process conditions in 
traditional pharmaceutical processing techniques call for alternative technologies. In 
the light of this development, RESS represents a more than fitting candidate. If future 
technological advances can further improve the efficiency and control of the process 
parameters, then research on scale-up is possibly the next step on the way of the RESS 
technique into the market.  
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 APPENDIX 
Modifications of the expansion path 
The expansion path for the production of RESS products as designed by Sitec is 
depicted in Figure 32a). The configuration allows interruption of the RESS process in 
case of clogging of the nozzle, but it has the disadvantage of the fluid passing through a 
long distance between the micro-metering valve and the nozzle inside the expansion 
chamber. The pressure loss caused phase transitions and thus product loss before the 
fluid passed the nozzle, which could not be prevented by additional heating. Thereby, 
clogging of the nozzle and thus interruptions of the RESS process occurred frequently 
and product yields were unstable. For this reason, alternative configurations were built 
in house and tested, which are depicted in Figure 32b) and c).  
a) b) c) 
 
 
 
Figure 32 Modifications of the expansion path a) Sitec configuration b) modified configuration 
with short distance between micro-metering valve and nozzle c) modified setup with short 
distance between micro-metering valve and nozzle and security valves between extraction and 
expansion chamber.  
a  valve V35 
b  micro-metering valve V45 for regulation of the CO2 flow through the nozzle 
c  nozzle 
d  Filter for particle collection 
e  security valve between extraction and expansion chamber 
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In configuration b), the distance between micro-metering valve and nozzle was 
shortened, which distinctly improved both the continuity of the expansion process and 
the product yields. If clogging of the nozzle did occur however, the process needed to 
be abandoned since no security valve could be operated between the extraction and the 
expansion chamber. Therefore, a security valve was added (Figure 32c). Configuration 
c combines both a short distance between micro-metering valve and the nozzle, and 
the possibility of process interruption if needed. 
Validation of the Stricker dissolution apparatus 
The sampling specifications for the Stricker flow-through cell apparatus are met, if the 
deviation of every individual sample volume is maximum 4 % of the intended sample 
volume, except for the first sample, since it cannot be avoided that a certain amount of 
air enters the apparatus while introducing the sample into the chamber. The chamber 
volume at the end of the experiment is allowed a total deviation of ± 5 %. To test if the 
equipment is within the specifications, 3 runs were performed, where during 30 min a 
sample of 3.5 ml was withdrawn and accurately measured every minute. The chamber 
volume at the end of the runs was determined. 
  
 Run Chamber volume [ml] Deviation allowed [ml] Satisfies 
1 97.5 5 yes 
2 99.0 5 yes 
3 101.0 5 yes 
Time (min) Sample volume 1 Sample volume 2 Sample volume 3 
0 3.5 3.5 3.5 
1 3.5 3.5 3.5 
2 3.5 3.5 3.5 
3 3.5 3.5 3.5 
4 3.5 3.5 3.5 
5 3.5 3.5 3.5 
6 3.5 3.5 3.5 
7 3.5 3.5 3.5 
8 3.5 3.5 3.5 
9 3.5 3.5 3.5 
10 3.5 3.5 3.5 
11 3.5 3.5 3.5 
12 3.5 3.5 3.5 
13 3.5 3.5 3.6 
14 3.5 3.5 3.5 
15 3.5 3.5 3.4 
16 3.5 3.5 3.5 
17 3.5 3.55 3.5 
18 3.5 3.5 3.5 
19 3.5 3.5 3.55 
20 3.5 3.5 3.5 
21 3.5 3.5 3.5 
22 3.5 3.5 3.5 
23 3.5 3.5 3.5 
24 3.5 3.5 3.5 
25 3.5 3.5 3.5 
26 3.5 3.5 3.5 
27 3.5 3.5 3.5 
28 3.5 3.5 3.5 
29 3.5 3.5 3.5 
30 3.5 3.5 3.5 
Mean [ml] 3.5 3.5 3.5 
St Dev [ml] 0.00 0.01 0.03 
Allowed dev[ml] 0.14 0.14 0.14 
Satisfies yes yes yes 
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UV calibration and quantitative determination of theophylline  
Theophylline solutions were quantified in phosphate buffer pH 7.4 at 270 nm. 5 stock 
solutions were prepared by accurately weighing an amount of TP (50 mg) and placing 
it into 100 ml volumetric flasks. The material was dissolved in 100 ml of phosphate 
buffer pH 7.4 and diluted appropriately. Each concentration was measured in 
triplicate. 
 
Figure 33 UV calibration curve of theophylline at 270 nm in phosphate buffer pH 7.4. Error 
bars represent standard deviation of the mean ( n = 6) 
 
UV calibration and quantitative determination of olanzapine 
Olanzapine was quantified at 260 nm in phosphate buffer pH 6.8 for dissolution 
testing. 3 stock solutions of 5 mg olanzapine in 250 ml buffer were prepared and each 
was diluted 5 times. For the quantitative determination of olanzapine in 
nanosuspensions, a calibration in 0.1 N hydrochloric acid (HCl) was used at a 
wavelength of 260 nm. 3 stock solutions of 10 mg olanzapine in 100 ml HCl were 
prepared and diluted 6 times. 
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Figure 34 UV calibration of olanzapine at 260 nm in phosphate buffer pH 6.8. Error bars 
represent standard deviation of the mean (n = 6) 
 
 
Figure 35 UV calibration curve of olanzapine at 260 nm in 0.1 N HCl. Error bars represent 
standard deviation of the mean (n = 6) 
  
y = 32,242x + 0,062 
R² = 0,99921 
0 
0,05 
0,1 
0,15 
0,2 
0,25 
0,3 
0,35 
0,4 
0 0,002 0,004 0,006 0,008 0,01 
A
bs
or
pt
io
n 
c(mg/ml) 
y = 41,045x + 0,0591 
R² = 0,99995 
0 
0,2 
0,4 
0,6 
0,8 
1 
1,2 
1,4 
1,6 
0 0,005 0,01 0,015 0,02 0,025 0,03 0,035 
A
bs
or
pt
io
n 
c (mg/ml) 
APPENDIX | xvii 
HPLC calibration and quantitative determination of ibuprofen and 
nicotinamide 
Ibuprofen and nicotinamide were quantified with HPLC at a detection wavelength of 
230 nm. 6 stock solutions were prepared of 8 mg API in 100 ml of phosphate buffer 
pH 6.4 and each stock solution was diluted 7 times. 
 
Figure 36 HPLC calibration over the peak area of ibuprofen. Error bars represent standard 
deviations of the mean (n = 6) 
 
Figure 37 HPLC calibration over the peak area of nicotinamide. Error bars represent standard 
deviations of the mean (n = 6) 
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